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This cross-sectional study reviews the relationship between periodontitis and chronic 
obstructive pulmonary disease (COPD) by exploring epidemiological and pathological data 
from patients with both diseases and a cohort with alpha-one antitrypsin deficiency (AATD).  
Diagnostic criteria for periodontitis is not well standardised in the literature and thus leads 
to diversity in reported prevalence.  In this study, the prevalence in non-deficient COPD 
patients was found to be increased (1.2 – 97.6%) in comparison to AATD patients (0 – 88.2%) 
regardless of the definition of periodontitis used (p<0.001), and both groups had a 
significantly higher prevalence than the general UK population.  Common risk factors to both 
diseases were associated with periodontitis but did not fully account for the increased 
prevalence.  Periodontitis prevalence did not relate to respiratory physiology in non-
deficient COPD, but correlations were seen in the AATD group. 
As periodontitis, COPD and AATD are all destructive, neutrophilic inflammatory diseases; 
they likely share a common pathophysiology and the role of peripheral and salivary CRP and 
IL-8 was explored.   Peripheral IL-8 and salivary and peripheral CRP levels were significantly 
higher in non-deficient COPD compared to AATD patients, but neither accounted for the 
increased prevalence of periodontitis in non-deficient COPD patients. 
To conclude, the criterion used to diagnose periodontitis in epidemiological studies has a 
significant impact on the published prevalence and associations with other chronic lung 
disease. This data finds increased prevalence in non-deficient COPD compared to AATD but 
the association with the severity of pulmonary impairment is stronger in AATD suggesting 
the deficiency enhances periodontal damage irrespective of other demographic 
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1.1 CHRONIC OBSTRUCTIVE PULMONARY DISEASE  
 
1.1.1 Definition 
Chronic obstructive pulmonary disease (COPD) is a chronic, progressive disease of airflow 
obstruction due to an enhanced chronic inflammatory response [1, 2]  resulting in airway 
remodelling and parenchymal destruction [3].  The most common symptoms include cough, 
breathlessness and sputum [4].  COPD is heterogeneous and includes different phenotypes 
including emphysema predominant and those with chronic bronchitis [5] but the extent to 
which phenotype is predominant is individual to the patient. 
Emphysema is the pathological enlargement of airspaces distal to terminal bronchioles with 
non-fibrotic destruction of alveolar walls.  Centrilobular emphysema is characterised by 
discrete enlargement of airspaces and is upper lobe predominant and is the type most 
associated with smoking related disease.  Panlobular emphysema affects the whole acinus 
more uniformly and is often seen in non-smokers [6, 7].  
Chronic bronchitis describes an inflammatory condition involving the bronchi, but also 
describes bronchial mucous gland enlargement and excessive mucus secretion.  This is 
usually defined as chronic or recurrent productive cough most days ≥3months per year for 




1.1.2 Diagnosis and Severity Classification 
The most frequently employed measure to diagnose  COPD is the presence of post-
bronchodilator FEV1:FVC ratio <70% [4].  Severity of disease is then classified according to 
the percentage of predicted FEV1.  GOLD stage 1 (mild) is characterised by FEV1 ≥80%; GOLD 
stage 2 (moderate) by FEV1≥50% but <80%; GOLD stage 3 (severe) by FEV1 ≥30% but <50% 
and GOLD stage 4 (very severe) by FEV1 <30% [4].   
 
1.1.3 Prevalence 
Prevalence data is widely variable due to methods of measurement, diagnosis and reporting 
but has been reported to be  9-10% in people ≥40years of age [8] with a global prevalence of 
11.7% [4]. There is evidence to suggest that COPD prevalence is increasing in the UK; by 27% 
in the last decade[9].  
 
1.1.4 Mortality and Economic Burden 
COPD accounts for 5.3% of total UK deaths and 26.1% of all deaths from lung disease [9]. 
In 2010, the cost of COPD in the USA was approximately US$50 billion, including $20 billion 
in indirect costs and $30 billion in direct health care expenditures [10].  In the UK the NHS 
annual cost is approximately £800 million, or £1.3 million per 100000 people [11].  COPD is 
associated with other chronic inflammatory conditions such as cardiovascular disease and 
diabetes which occur at a higher prevalence than seen in age-matched patients without 




1.1.5 Risk factors 
Cigarette smoking remains the main risk factor for the development of COPD in the 
developed world.  However, not all smokers develop disease and COPD is seen with other 
environmental exposures [14] and in non-smokers [15].   Familial and genome wide 
association studies suggest there is a genetic susceptibility to COPD with the most 
documented being alpha-1 antitrypsin deficiency (AATD) [16](see section 1.2). 
 
1.1.6 Pathogenesis 
COPD results from an abnormal and excessive inflammatory response to noxious stimuli in 
the lungs leading to destruction of tissues [17].  The ongoing activation of innate and 
acquired host inflammatory responses eventually results in lung damage [18].  Contributing 
to excessive inflammation, there are two processes hypothesised to be  involved in the 
pathogenesis of COPD; the proteinase-anti-proteinase theory [19] and the oxidative stress 
theory [18].   
The proteinase-anti-proteinase hypothesis states that tissue destruction occurs when the 
action of proteinases is no longer controlled by anti-proteinases.  This can occur due to 
genetic factors e.g. AATD, functional loss of anti-proteinases through proteolytic or oxidative 
damage, or due to excessive recruitment or activation of proteinases [19].   
The oxidative burden is increased in COPD. The main source of excess oxidant is cigarette 
smoke, but additional oxidants can also be released by inflammatory cells such as 
neutrophils [20, 21].  Oxidative stress inactivates anti-proteases, amplifying inflammation 
[22].   
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1.1.7 Inflammation in COPD 
COPD is also associated with enhanced inflammation systemically, with studies describing 
the activation of inflammatory mediators and the secretion of cytokines [23].  Cigarette 
smoke and other atmospheric noxious substances can directly activate many cells including 
those of the respiratory epithelium to release cytokines and chemokines leading to 
inflammatory responses and tissue destruction [3, 24].  In susceptible individuals this 
inflammation is sustained even after smoking cessation [25].  The mechanism of systemic 
inflammation resulting from pulmonary inflammation is not clear but may result from an 
overspill of cytokines from the airways into the systemic circulation; such as seen with 
Surfactant Protein D- a glycoprotein only produced by type 2 pneumocytes, yet found in 
peripheral circulation of patients with COPD [26], cellular cross talk between  respiratory and 
systemic compartments (e.g. release of microvesicles into the circulation as seen by 
increased numbers of circulating endothelial microparticles of pulmonary origin in patients 
with COPD exacerbations [27]) or the presence of local inflammatory mediators causing  
peripheral release of other mediators and cytokines [28].   Increased inflammatory 
mediators and cytokines have been seen in the peripheral circulation of COPD patients, and 
are more pronounced during exacerbations [29-31]. 
 
1.1.8 Neutrophils in COPD 
Neutrophils are the most abundant circulating leucocyte, derived from pluripotent stem cells 
in bone marrow and characterised by multilobed nuclei and cytoplasmic granules.   
6 
 
Neutrophils are the predominant cell seen in airway secretions in COPD and have been 
implicated in causing tissue damage by extracellular release of destructive mediators such as 
the proteinases neutrophil elastase and proteinase 3 [3]. 
Many studies have shown an increase in neutrophils in both systemic circulation and airways 
of smokers and patients with COPD.   Bronchoalveolar lavage (BAL) fluid from chronic 
smokers shows dose-dependent increased level of neutrophils when compared to non-
smokers [32], and numbers were highest in induced sputum of smokers and COPD patients 
than non-smokers, with the highest levels being seen in severe COPD patients, correlating 
with FEV1 percent predicted [21].  Peripheral and airway neutrophil counts have been 
shown to be positively related to accelerated decline in FEV1 in COPD patients [33-35].   
The neutrophils from COPD patients also appear dysfunctional.  Circulating neutrophils 
produce more reactive oxygen species (ROS) than those from healthy non-smokers or 
smokers with normal lung function [20], and have enhanced, rapid and tortuous chemotactic 
responses to inflammation and increased degranulation and tissue destruction both in vitro 
and systemically [36, 37].  
The level of neutrophilic inflammation in airways correlates with disease severity and 
progression in COPD whether measured by lung physiology, radiologically or self-reported 
health status [21, 33-35, 38].  This supports the concept that activated neutrophils play an 
important role in lung injury including development of emphysema through neutrophilic 
release of inflammatory cytokines and proteases [39-41].  Cigarette smoking enhances 
recruitment of activated neutrophils with increased release of tissue destructive proteinases 
[42],  supporting the faster physiological decline seen in COPD patients who continue to 
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smoke.  Importantly, neutrophilic inflammation is sustained in ex-smokers with COPD 
although it abates in ex-smokers without COPD [43] again suggesting susceptibility to self-
perpetuating inflammation. 
 
1.1.9 Co-morbidities in COPD 
COPD is recognised as having a series of co-morbidities hypothesised to be related to a 
systemic or common organ specific inflammatory process.  This presence of co-morbidity is 
reflected in the updated GOLD classification systems for COPD [4].  An observational study 
found more than 97% of a COPD cohort had at least one other co-morbidity, with more than 
50% having at least 4 [44] when systematically sought.  Respiratory co-morbidities 
associated with COPD include bronchiectasis [45], asthma, pulmonary fibrosis [46] and lung 
cancer [46], but extra thoracic chronic inflammatory disease also co-occurs [47].  
Cardiovascular diseases are the most common [48] including hypertension [46], venous 
thromboembolism, ischaemic heart disease, arrhythmias [46, 49] and heart failure [46, 50].  
Non-cardiovascular co-morbidities include cognitive impairment [51], diabetes [48, 52], 
skeletal muscle dysfunction [53], low bone mineral density and osteoporosis [50, 54].  This 
high prevalence may reflect the presence of common risk factors including age, smoking and 
sedentary lifestyle, but even when such factors are accounted for, there remains increased 





1.2  ALPHA-1 ANTITRYPSIN DEFICIENCY 
 
1.2.1 Definition 
Alpha-1 antitrypsin (AAT) is predominantly synthesised in the liver [55] and its primary 
function is the inhibition of neutrophil elastase (which it inhibits on a one-to-one molar 
basis).  However AAT also has an anti-inflammatory role regulating the expression of many 
pro-inflammatory cytokines [56].   Alpha-1 antitrypsin deficiency (AATD) was first described 
in 1963 where it was noted that serum from patients with early, severe emphysema lacked 
α1 bands [57]. 
Although there are more than 100 detectable alleles for AAT, the most common variants are 
M, S and Z alleles.  The M allele is the wild type, and is the most prevalent variant, providing 
adequate levels of AAT, whilst the Z allele is the most common deficiency variant in northern 
Europeans [58]. Null variants are characterised by a complete absence of circulating AAT due 
to transcriptional or translational errors interrupting their synthesis [59]. 
Patients with AATD, in particular homozygotes for Z allele are at increased risk for the 
development of early onset, severe emphysema and airflow obstruction [60].  This risk is 
increased in patients who smoke cigarettes but can occur in non-smokers.  Patients with 




1.2.2 Diagnosis and Severity Classification 
Individuals with normal alleles for AAT generally have serum concentrations of AAT of 20–
53mol/L.  Deficient alleles generate concentrations < 20mol/L, but in severe cases of 
AATD such as homozygotes for Z allele, the concentration is <11mol/L with only 15-20% of 
normal circulating AAT present [59]. 
Aside from measuring concentration of circulating AAT in serum, genotyping is also 
recommended as it has the advantage of identifying null genes, rare deficiency alleles and 
forms of AATD where the level of the protein is normal, but has abnormal function [61]. 
 
1.2.3 Prevalence 
AATD is an autosomal co-dominant disorder affecting 1 in 3000 live births [62].  Accurate 
prevalence data is lacking but it is suggested that the prevalence in England is 8.1 per 1000 
population for the more severe, PiZZ genotype [63]. 
 
1.2.4 Morbidity & Mortality 
A UK longitudinal study of patients with PiZZ AATD revealed that FEV1 GOLD stage, Kco and 
GOLD group were estimated to be the most significant factors related to mortality.  For all-
cause mortality, patients in GOLD group D had a survival of less than 40% at 15years 
compared to more than 70% in groups A, B and C [64].  
A review of the American National Heart, Lung, and Blood Institute Registry of Individuals 
with Severe AAT Deficiency found an overall 5-year mortality rate of approximately 3% per 
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year and those with initial FEV1 < 15% predicted had a significantly higher mortality rate than 
those with FEV1 percentage of predicted > 50%.  The most common causes of death were 
emphysema and cirrhosis [65]. 
A significant relationship exists between smoking and lung function decline in adults with 
PIZZ.  Research has shown current smokers have more decline in FEV1, whereas ex and 
never smokers show a slower decline [66].   Long-term loss of lung function also correlates 
with the incidence of respiratory infections and exacerbations [67, 68]. 
 
1.2.5 Pathogenesis 
Emphysema in AATD is thought to develop due to excess levels of unopposed neutrophil 
elastase in the lung [69] resulting in a wider area of tissue destruction [70].  In individuals 
with PiZZ, the Z allele can also act as an additional chemoattractant for neutrophils, 
perpetuating their recruitment [71].  As with usual COPD, there is significant heterogeneity 
in patient presentation and cigarette smoking can cause oxidative and proteolytic 
inactivation of AAT [72] function, contributing to the noted accelerated clinical decline.  
 
1.2.6 Co-morbidities in AATD  
Less data is available on diseases commonly seen as co-morbid with AATD but AATD patients 
with PiZZ or PiZnull genotype have a higher prevalence of inflammatory bowel disease and 
hypothyroidism than that predicted for the general UK population; (1.5 vs 0.4%), and (8.5 vs 
1.2% of women and 0.4% of men) respectively.  In the same study, 0.8% of patients had a 
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diagnosis of Wegener's granulomatosis and 0.9% had panniculitis [73].  Conflicting evidence 
is available for the association of AATD and bronchiectasis, pancreatitis, cardiovascular 
disease and renal disease [74]. 
 
1.2.7 AATD as a mechanistic model 
Investigating relationships with COPD and other diseases can be hampered by confounders 
such as smoking, age and severity of airflow obstruction which can be difficult to correct for.  
For this reason, patients with AATD are often used as a comparative group to usual COPD 
patients as AATD is characterised by an exaggerated inflammatory response, similar to usual 
COPD but usually identified at an earlier age [74] earlier stage of disease [75] and many of 
these patients have not usually been exposed to the significant environmental risk factors 














Periodontitis is a common, chronic, bacterial-initiated inflammatory disease.  The 
accumulation of a biofilm above and below the gingival margin leads to a dysbiosis, which 
drives a dysfunctional host-immune-inflammatory response, leading to connective tissue 
destruction and the formation of a periodontal pocket [78].   Without treatment, the 




Periodontitis is usually diagnosed in the presence of a combination of periodontal 
inflammation, (bleeding on probing (BOP) of the gingiva), number and depth of periodontal 
pockets, level of clinical attachment loss (CAL) and presence of radiologically evaluated 
alveolar bone loss [79-81].  Probing pocket depth (PPD) and CAL are measured using 
purposefully designed periodontal probes.  The PPD is the distance from the gingival margin 
to the base of the gingival sulcus (or periodontal pocket).  CAL is the distance from the 




Figure 1: Measurement of clinical attachment loss and probing pocket depth in the assessment of 
periodontitis.  Note. Adapted (with permission) from "Understanding Periodontal Diseases: 
Assessment and Diagnostic Procedures in Practice: 1" by Iain L.C. Chapple, Angela D. Gilbert, Nairn 
H.F. Wilson, 2002, Published by Quintessentials: Endontics 
 
However, there is no consistent use of one definition of periodontitis in the literature.   
Despite the clear criteria defined by the American Association or Periodontology [97], a 
systematic review found only 15/104 studies providing any proposed definition of 
periodontitis [81] and published studies use a range of periodontal measurement 
parameters for analysis [82-86] reflecting the lack of a uniformly applied definition of 
periodontitis [82-88, 90-94] in epidemiological studies.  Classifying periodontitis has been 
the subject of many changes and reviews [79-81, 95, 96]. National Health Examination 
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Surveys have been conducted in the United States since 1960, and indices of measurement 
in these surveys have evolved from visual inspection of inflammation to a combination of 
PPD, CAL and furcation involvement [79]. 
PPD is generally accepted as a reflection of current disease status, whilst CAL represents 
cumulative disease experience [94].  In younger populations, PPD and CAL correlate well, but 
as people age, gingival recession and therefore measures of attachment loss become a 
normal part of the ageing process.  Increased PPD can occur as a false positive clinical finding 
when gingival tissues become swollen due to inflammation hence moving the gingival 
margin upwards (false pocketing). The use of CAL alone may over estimate periodontitis 
because attachment loss can occur with non-inflammatory gingival recession, e.g. trauma 
from over tooth brushing [79]. 
There have been attempts to provide a unifying definition for periodontitis.  The Division of 
Oral Health at the Centers for Disease Control and Prevention (CDC) alongside the American 
Academy of Periodontology (AAP) defined severe periodontitis as involvement of two or 
more interproximal sites with CAL ≥6mm and one or more interproximal sites with PPD 
≥5mm.  Moderate periodontitis required involvement of two or more interproximal sites 
with CAL ≥4mm or ≥2 interproximal sites with PPD ≥5mm [79].  Since then, Eke et al 
additionally defined mild periodontitis as ≥2 interproximal sites with attachment loss ≥3mm 
and ≥2 interproximal sites with PPD ≥4mm, or one with PPD ≥5mm [97].    During the 2005 
5th European Workshop in Periodontology a two-threshold level criterion was proposed to 
diagnose periodontitis.  This was the presence of attachment loss of ≥3mm in ≥2 non-
adjacent teeth to diagnose incipient cases and the presence of proximal attachment loss of 
15 
 
≥5mm in ≥30% of teeth to determine severe disease.  However, the authors stated that a 
single index measurement does not reflect the disease and that these criteria are designed 
for use in studies determining risk factors for, and not the prevalence of, periodontitis [96]. 
The current American classification system is based on the 2014 task force meeting who 
developed a clinical interpretation of the 1999 International Workshop for a Classification of 
Periodontal Diseases and Conditions proposal [98], recognising the importance of 
attachment levels but also difficulties in accurate measurement and interpretation especially 
in those with non-inflammatory recession [99]. 
The Basic Periodontal Examination (BPE) recommended by The British Society of 
Periodontology in clinical practice [100] is used routinely in the UK which defines evidence of 
periodontitis being present when the PPD is ≥3.5mm but does not utilise measurements of 
CAL in its definitions. 
 
1.3.3 Prevalence 
Accurate prevalence data is limited given the lack of a uniformly accepted definition for the 
diagnosis of periodontitis.  However, the most recent adult dental health survey reports that 
periodontitis affects approximately 45% of adults [101], with 8-11% of adults suffering from 
severe periodontitis [101, 102].  In this survey, periodontal health was recorded in the 
absence of bleeding, calculus, periodontal pocketing of 4mm or more and in the case of 




1.3.4 Morbidity  
Periodontitis is an important public health concern given the consequences of tooth loss, 
including maintaining nutrition, effects on speech production and the financial burden 
associated with its treatment estimated to be £2.8 billion in the UK in 2008 [103].  
Periodontitis has also been linked to other chronic systemic diseases including diabetes 
mellitus [104, 105], rheumatoid arthritis [105, 106], and cardiovascular diseases. 
 
1.3.5 Risk factors 
There are several well recognised risk factors for the development of periodontitis.  The 
most reported are age [107-109]and smoking [107, 110, 111], with prevalence and severity 
increasing as patients’ age and in those with a significant smoking history.  Others include 
diabetes, poor dental habits [109, 112]and low socio-economic status [101, 109, 111]. 
Evidence has shown that people taking long term corticosteroids have increased CAL and 
deeper PPD [113].  Inhaled corticosteroids also affect bone mineral density and increase the 
risk of tooth loss [114] and inhaled beta-2 agonists reduce salivary production and thus a 
consequent decreased output of antibacterial components which promotes bacterial 
colonization, plaque growth and potentially periodontitis [115].  There is no evidence that 
LAMA use has any relationship with periodontitis but a dry mouth is a commonly reported 
side effect due to reduction in oral fluid production and reduced salivary flow has been 





The pathogens implicated in periodontitis adhere to the gingival margins and produce 
biofilms which induces a local inflammatory response activating host innate and acquired 
immune pathways.  This results in local infiltration of gingival tissues with neutrophils and 
other inflammatory mediators including cytokines, chemokines and neutrophil derived 
proteases.  The active periodontal lesion is B-cell and neutrophil dominant with repeated 
bacteraemia causing activation of the acute-phase response and subsequent systemic 
inflammation [116].  This is thought to prime peripheral blood neutrophils causing an 
exaggerated release of ROS and pro-inflammatory cytokines [117], which can lead to 
breakdown of supporting structures and destruction of bone in susceptible individuals. 
 
1.3.7 Neutrophils in Periodontitis 
Periodontitis is characterised by a neutrophilic infiltrate [118].  Systemic neutrophil 
chemotaxis studies in chronic periodontitis showed reduced speed (movement in any 
direction), velocity (speed of movement towards the chemoattractant) and accuracy (of 
movement towards the chemoattractant) of neutrophils [119] which improved after 
treatment of the periodontitis [120].  This observation supports the notion of a causal link 
between periodontitis and systemic cell function.    Impaired neutrophil function could 
render the host less able to deal with the burden of bacteria in the periodontium, thereby 




Further supporting the link between neutrophils and periodontitis there is an increased 
prevalence of periodontitis in conditions characterised by abnormal neutrophil function 
[121],  including defective neutrophil production (autoimmune or chemotherapy induced 
neutropenia) defective neutrophil release from bone marrow as seen in WHIM (warts, 
hypogammaglobinaemia, infections, and myelokathexis), inherited leucocyte adhesion 
deficiency, excessive neutrophil activation, deficient clearance of neutrophils as in 
autoimmune inflammatory diseases including systemic lupus erythematosus and the 
Papillon Lefevre syndrome(neutrophil cathepsin C deficiency). 
 
 
1.4 PERIODONTITIS AND SYSTEMIC DISEASE 
 
1.4.1 Periodontitis and Systemic Co-Morbidity 
Periodontitis has also been linked to a number of other chronic systemic diseases including 
diabetes mellitus [104, 105], rheumatoid arthritis [105, 106], cardiovascular diseases [122-
124] and stroke [125, 126]. 
 
1.4.2 Periodontitis and Respiratory Disease 
A meta-analysis identified 11 observational studies of intubated patients where periodontal 
disease was associated with respiratory infections [127]. Half of these studies link the 
patient’s dental status to the development of a ventilator-associated pneumonia, and one 
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study reported the implicated pathogen had first colonized the dental plaque biofilm [128].  
Other studies have demonstrated an association between poor dental status, the presence 
of oral bacteria and occurrence of pneumonia [129-132], although these studies were 
predominantly undertaken in patients admitted to intensive care or residing in care homes 
rather than the general population.  
Another meta-analysis [127] included several intervention trials (improved oral hygiene and 
use of antibiotics for oral disease) [133-137]  to reduce the bacterial load in the mouth.  It 
found these treatments significantly reduced the risk of developing pneumonia, supporting a 
causal link between oral pathogens and lower respiratory tract infections.  Furthermore, the 
use of mouthwashes in intubated patients can reduce the nosocomial respiratory infection 
rate [138, 139]. 
The association between poor dental health and respiratory disease is believed to exist as a 
result of dental plaque becoming colonized with respiratory pathogens and subsequently 
acting as a periodontal reservoir for infectious micro-organisms.  This is more problematic in 
patients who are already compromised due to frailty or ill health as they are more likely to 
aspirate oral secretions containing these pathogens and struggle to clear them from the 
respiratory tract by normal protective mechanisms [86, 129].  
 
1.4.3 Periodontitis and COPD 
There is evidence that COPD and periodontitis occur more commonly in the presence of the 
other [83, 84, 86-88, 92, 94, 140-145], but published studies are variable in approach.  Some 
authors assessed the prevalence of periodontitis patients having COPD as co-morbidity, 
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whilst others have assessed the prevalence of patients with COPD having periodontitis as co-
morbidity.   
Studies assessing COPD as a co-morbidity of periodontitis have all described an association, 
but of varying strength. A meta-analysis representing 3988 COPD patients and 22871 
controls reported a pooled odds ratio (OR) for having COPD in populations diagnosed with 
periodontitis as 2.08, (95% CI 1.48-2.91; p<0.001) [143].  Hayes et al found for each 20% 
increase in mean whole mouth alveolar bone loss, a person’s risk for subsequently 
developing COPD was increased by 60% [141], whilst a link was found between poor oral 
health status with bacterial colonisation and the presence of COPD in chronic care facility 
residents [146].  A large cross sectional study correcting for age, smoking, socio-economic 
status and dental habits, found moderate periodontitis was associated with COPD in male 
patients only and the relative risk of severe periodontitis in the male group was 1.23 (95% CI 
1.06-1.56) [92].  The lack of a link in women may have been due to insufficient power in the 
female group. 
Studies assessing the co-morbid prevalence of periodontitis amongst patients with COPD 
have found similar results.  Data from a longitudinal COPD cohort study found a significantly 
increased cumulative incidence of increased periodontitis with adjusted hazard ratio (HR) of 
1.20 (95% CI 1.15-1.25) rising to 3.17 (95% CI 2.81-3.57) in a sub group requiring 
hospitalisation for COPD [144]. A further in-patient study noted increased markers of 
periodontitis in a hospitalised COPD group compared to an in-patient control group (PPD 
2.57 +/-0.85 vs 1.76 +/- 0.7, p<0.0001 and CAL 3.16 +/- 0.53  vs 2.12 +/- 0.92, p<0.0001) [83].  
Several studies assessing non-exacerbating COPD and periodontitis report worse periodontal 
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indices in patients with COPD when compared to non-COPD controls [84, 86-88].   Leuckfeld 
et al assessed orthopantomograms in a retrospective cross sectional study of patients 
evaluated for lung transplant and found a significant difference in radiographically 
determined periodontitis, with 44% of COPD patients affected compared to 7% of non-COPD 
patients [145].   
However, other studies have failed to find such associations [85, 90, 93].  Bergstrom et al 
found that smoking rather than COPD was the major risk factor for the existence of 
periodontal pockets [93], and the NHANES III survey were unable to identify any relationship 
between COPD and periodontitis [90].  Kim et al found a relationship with airflow 
obstruction in males and loss of natural teeth, but no relationship with periodontitis [91]. 
These conflicted studies may reflect inconsistency in case definitions, data collection and 
analysis.  Additionally, not all studies describing an association between COPD and 
periodontitis correct for potentially significant confounding factors. For example, a meta-
analysis that reported a pooled odds ratio for having COPD in populations with periodontitis 
as 2.08, (95% confidence interval 1.48-2.91; p<0.001) reduced this to 1.78 (95% CI 1.23-2.58) 
following correction for age, gender and smoking [143].  There remains some uncertainty, 
therefore, whether the association between COPD and periodontitis simply reflects the 
shared risk factors of age, smoking, dental habits and socio-economic group. 
 
1.4.4 Neutrophils linking periodontitis & COPD 
As described already, neutrophil dysfunction occurs in both COPD and periodontitis.  Both 
diseases are characterised by non-resolving inflammation and the subsequent activation and 
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consequences of the actions of neutrophils as a part of the host response to this persistent 
inflammation.   
 
 
1.5 C- REACTIVE PROTEIN 
 
1.5.1 Introduction 
CRP is predominantly synthesised in the liver [147] and is a major acute-phase plasma 
protein, the concentration of which can reach a 1000-fold increase in response to 
inflammation or tissue injury within 24–48 hours of the insult [148, 149] and fall rapidly after 
resolution of the precipitating event [149].   
Experiments have shown CRP can reduce the chemotactic responses of neutrophils [150, 
151] but also enhances phagocytosis [150].  CRP can also interrupt the adhesion of 
neutrophils to endothelium [152] and thus impede their migratory capacity. 
Raised systemic CRP levels have been associated with an increased risk of cardiovascular 
disease [153-156], diabetes [157], stroke [154, 156, 158] and death from these diseases 
[157, 159]. However, there is no consensus whether high levels of CRP are part of the 
mechanism through which inflammation contributes to these disease processes or whether 




1.5.2 CRP and COPD 
Published evidence supports an association between CRP and the presence of COPD.  A 
meta-analysis of five studies by Gan et al confirmed a significant increase in CRP levels in 
COPD patients compared with controls [160].  The ECLIPSE study found baseline CRP levels 
were significantly higher in COPD patients compared to smoking and non-smoking controls 
[161].  Similar findings of increased CRP have been seen with patients with airflow 
obstruction confirmed on spirometry and pre-existing diagnoses of COPD [28, 162, 163].  He 
et al also note a positive correlation between sputum and blood CRP levels in the COPD 
patients; r = 0.443, P < 0.01 [21], suggesting local inflammation in the respiratory tract 
promotes systemic inflammation causing a rise in blood CRP alongside sputum CRP. 
 
There are studies which have found significant associations with levels of CRP and lung 
function in COPD patients [21, 147, 162, 164-167].  Other studies note an association 
between CRP and exercise capacity [162, 163] and oxygenation [162, 166] and higher CRP 
levels over time have been associated with a faster FEV1 decline [33, 165].  Further studies 
have found an association with CRP and exacerbations of COPD [161, 166], and CRP has 
been found to be a significant predictor of hospitalisation and mortality in patients with 
chronic respiratory failure [168]. Many COPD patients use inhaled corticosteroids (ICS), and 
interestingly, the CRP level in COPD ICS users was found to be significantly lower than in 
those not using ICS [163]. 
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The mechanism of systemic inflammation in COPD is not yet clear, but overspill of ROS and 
cytokines from airways into systemic circulation or peripheral liberation of pro-inflammatory 
cytokines by inflammatory and/or structural cells are feasible hypotheses. 
 
1.5.3 CRP and Periodontitis 
CRP has been shown to be raised in the peripheral circulation of patients with periodontitis 
when compared to people without periodontitis [169-172].  Serum CRP has also shown to be 
correlated with the presence of bleeding on probing of the gingiva and the number of 
pathological periodontal pockets [173]. 
There is considerable evidence supporting treatment of periodontitis, (non-invasive and 
surgical), successfully reduces the level of circulating CRP [174-181], and a reduction in 
peripheral CRP is associated with an improvement in measured periodontal indices [178, 
181]. 
 
1.5.4 Salivary CRP 
The use of salivary CRP as a diagnostic tool has received increasing attention due to its easy 
availability and non-invasive collection methods[182].  Several studies have reported the 
potential use of salivary CRP as a clinical biomarker in thyroid disease [183] , metabolic 
syndrome [184], myocardial infarction[185, 186] atherosclerosis [187], COPD [83, 188] and 
periodontitis [189].  In studies comparing salivary and circulating CRP levels, results show a 
good correlation between the two [83, 186-188, 190, 191]. 
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CRP ELISA kits have been previously validated for use in saliva and found to show reasonable 
association with peripheral CRP [192, 193]. However there are reports where this 
association has not been seen [194] and in one validation study, several samples had salivary 
CRP values that exceeding more than 2 standard deviations from the mean reported by the 
manufacturer of the ELISA kit and despite dilution, adequate spike and recovery was not 
reliably achieved [193]. 
 
1.5.4.1 Salivary CRP in COPD 
Bhavsar et al measured serum and salivary CRP in a review of COPD and oral health status.  A 
significant positive correlation between serum and salivary levels in patients and controls 
was seen, but CRP levels were significantly higher in the COPD patients [83]. 
Patel et al also measured serum and salivary CRP in patients with COPD, smokers with 
normal spirometry and never smokers and found that salivary CRP correlated with serum 
CRP but was approximately 200 times lower than serum CRP.  The authors reported an 
increased CRP in COPD patients and smokers compared with never-smokers [188], a finding 
replicated by  Azar et al [195].  Patel et al, found acutely exacerbating COPD patients had a 
significantly increased salivary CRP in comparison to non-exacerbating patients.  No 
association was observed between salivary CRP and FEV1, but it was weakly correlated with 




1.5.4.2 Salivary CRP in Periodontitis 
There is limited published evidence on studies looking at salivary CRP in periodontitis, as 
much of the literature examines CRP in gingival crevicular fluid [171, 196, 197].  However, 
Shojaee et al found salivary CRP levels in patients with chronic periodontitis were higher 
than those for healthy controls, and report positive correlations between CRP and 






Interleukin-8 (IL-8) is a pro-inflammatory cytokine synthesized in response to an 
inflammatory insult.  It is a member of the neutrophil-specific CXC subfamily of chemokines 
and is a potent neutrophil chemotactic and activating factor and can be secreted from many 
host cells. 
 
1.6.2 IL-8 in COPD 
Several studies have reported increased levels of IL-8 in the sputum of patients with COPD 
[3, 38, 43, 198] and IL-8 levels also appear to correlate with the bacterial load in the airways 
[3], measures of disease severity [199] and airflow limitation [38, 198, 199].  Bhowmik et al 
found increased sputum IL-8 was associated with increased neutrophil counts in COPD 
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patients in a stable state and  significantly higher IL-8 levels in patients classed as frequent 
exacerbators [200]. 
Measurement of peripheral circulating IL-8 is unreliable and produces conflicting results [38, 
201, 202].  Circulating IL-8 is not always detectable in COPD patients, and is frequently 
undetectable in healthy individuals [29, 38].  Peripheral IL-8 does not always correlate with 
sputum levels, airflow obstruction [38] or smoking status [201]. 
Kuschner et al found dose related higher levels of IL-8 in the bronchoalveolar lavage (BAL) 
fluid of smokers compared to non-smokers.  They also report a significant association 
between the numbers of neutrophils in the BAL and the IL-8 in the BAL, consistent with the 
known established neutrophil chemoattractant effects of IL-8 [32]. 
 
1.6.3 IL-8 in Periodontitis 
In periodontitis, microbial toxins stimulate connective tissue epithelial cells to release 
inflammatory mediators including IL-8, which can then can pass through the connective 
tissue epithelium and enter the gingival crevicular fluid (GCF) [203].  
However, there are conflicting results regarding levels of IL-8 in GCF of periodontitis patients 
with some studies reporting lower levels in disease [204] and others significantly higher 
levels in periodontitis  [203, 205, 206].   There is also evidence to suggest treatment of 
periodontitis reduces the levels of IL-8 in GCF [205] and levels correlate with clinical 
periodontal parameters [203, 207].  Similarly conflicting results exist for peripheral IL-8 in 
the circulation of patients with periodontitis with some evidence for there being no 
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difference in health and disease [208] and other evidence that plasma IL-8 is raised in 
periodontitis [209]. 
Some studies have investigated salivary IL-8, but found it was detectable in only 50 % of 
participants, and with no significant difference in the levels between those with 
periodontitis and healthy controls.  However, weak but significant correlations were seen 




There is evidence suggesting that periodontitis and COPD could be co-morbidities of each 
other but variable definitions of disease, lack of uniformly applied diagnostic criteria and the 
presence of significant confounders weakens the current evidence.  The mechanisms 
underlying the potential association are yet to be fully explored but likely centre around the 









1.8 Study Hypotheses 
1.8.1 The prevalence of periodontitis is increased in patients with COPD and AATD 
compared to the prevalence in the UK general population as quoted in published 
literature.  
 
1.8.2 This increased prevalence reflects shared pathogenic mechanisms of 
neutrophilic inflammation, and so will relate to the severity of the lung disease. 
 
 
1.9 Study Aims 
1.9.1 To calculate the prevalence of periodontitis in COPD and AATD patients and 
importantly, determine this using the different definitions of periodontitis 
previously described and correct for common confounders. 
 
1.9.2 To validate commercially available ELISA kits for the measurement of salivary 
CRP and salivary IL-8. 
 
1.9.3 To measure CRP and IL-8 in peripheral blood and saliva and correlate with 
indices of lung function and disease severity. 
 
1.9.4 To measure CRP and IL-8 in peripheral blood and saliva and correlate with 















All patient recruitment, collection of data and biological samples and experiments 
conducted were done so with ethical approval from the National Research Ethics Service 
(REC13/WM/0044) and all patients provided informed written consent to take part. 
 
2.2 Patient cohort 
Patient characteristics are described in Chapter 3.  Non-AATD COPD patients were recruited 
from the Chronic Disease Resource Centre (CDRC) COPD cohort.  AATD patients were 
recruited from the Antitrypsin Deficiency Assessment and Programme for Treatment 
(ADAPT) cohort at Queen Elizabeth Hospital Birmingham, between 2014 and 2016.   
COPD was diagnosed by post bronchodilator spirometry  and staged by GOLD criteria [17].  
The AATD patients included only those with the PiZZ and PiZ0 null genotypes (confirmed by 
isoelectric focusing of finger prick blood spots at Heredilab Salt Lake City USA).  
Patients were not recruited if they had any medical condition precluding a dental 
examination, were unable to perform lung function tests to ERS/ATS standards or had 
significant alternative lung diseases.  All patients were in the stable state and exacerbation 
free for at least 6 weeks prior to review. 




2.3 Pulmonary Function Testing 
All patients had pulmonary function testing performed by appropriately qualified 
Respiratory Physiologists at Queen Elizabeth Hospital Birmingham.  All testing was done in 
concordance with International Guidelines [211].  Percent of predicted lung function values 
[212] were chosen for all analysis of lung function parameters as these correct for age, sex 
and height.   
 
2.4 Blood Samples 
30ml of peripheral venous blood was taken from each patient using the BD Vacutainer 
system® (Becton, Dickinson and Company, Plymouth, UK).  The first aliquot was allowed to 
clot and then serum was removed for routine testing in the hospital clinical laboratories.  
The second aliquot was collected into lithium heparin tubes to obtain plasma.  This was 
prepared by centrifugation at 3000rpm for 10minutes at 4°C and then collection of the 
supernatant which was subsequently stored at -80°C.   
 
2.5 Saliva Samples 
Patients were asked to not eat, drink, smoke or brush teeth prior to sampling appointment. 
Sterile water was used by the patient to rinse their mouth, then after 10 minutes, a sterile 
marble was placed in the mouth to stimulate saliva production which was then expectorated 
into a sterile tube.  
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The saliva was stored on ice before centrifugation at 2,500 rpm for 10 minutes at 4°C to 
remove debris. The supernatant was snap frozen in liquid nitrogen and subsequently stored 
at -80°C until analysis.  
 
2.6 Clinical Review 
All patients attended the department on one occasion and underwent a clinical review by a 
trained respiratory physician to ascertain the following:  Age, BMI, past medical history, 
medications and smoking history.  Respiratory symptom burden was assessed using the 
modified Medical Research Council scale (mMRC scale) [213] which is the most commonly 
used validated scale to assess dyspnoea in daily living in chronic respiratory diseases [213]. 
Bronchitis was defined as self-reported cough and sputum production for at least 3 months 
of the year on two consecutive years and annual exacerbation rate (increase in symptoms 
usually requiring an increase in medication) was self-reported.  Note was also made of 
medication use and a review of previous thoracic CT scans was undertaken to assess for 
radiological evidence of emphysema. 
 
2.7 Dental Examination 
A fully qualified dentist conducted a general oral examination and recorded the number of 
teeth present. Periodontal measurements were carried out on all teeth present using the 
UB-WHO-CF15 periodontal probe (Implantium.co.uk). For each tooth, 4 sets of periodontal 
measurements were taken; the pocket probing depth and clinical recession on the mesial 
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and distal aspects of the buccal and palatal/lingual surfaces. In order to standardise all of the 
measurements taken the same criteria were used in each examination.  Measurements were 
taken as per standard dental examination procedures.  The probing depth was measured to 
the nearest millimetre from the base of the periodontal pocket to the gingival margin. The 
recession was measured to the nearest millimetre from the cement-enamel junction (CEJ) to 
the gingival level [79].  f the gingival level was at the CEJ, the recession was recorded as 
0mm.  The total attachment loss was recorded as the sum of the probing depth and 
recession. A dichotomous record of bleeding on probing (BoP) was recorded as either 
present or absent for each site probed.  These periodontal measurements allowed for 
determination of the presence of periodontitis as per the definitions outlined in Section 3.2. 
 
2.8 Demographic Questionnaire & Assessment of Socio-
economic Status 
All patients were asked to complete a questionnaire at the time of dental assessment.  This 
included questions on current residential postcode, age at leaving full time education and 
qualifications gained, current and where applicable, previous employment status, category 
of occupation and household income, see Appendix 1.   
Socio-economic data was determined by calculating the English Index of Multiple 
Deprivation (IMD) score and the National Statistics Socio-economic Classification (NS-SEC) 
score.  IMD score was determined by the self-reported residential postcode of each 
individual and comprises 7 elements of deprivation: Income Deprivation; Employment 
Deprivation; Health and Disability Deprivation; Education, Skills and Training Deprivation; 
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Barriers to Housing and Services; Crime Deprivation and Living Environment Deprivation 
[214].  NS-SEC defines socio-economic position by employment category [215] and was 
determined by the self-reported occupation of the patients. 
 
2.9 Dental Questionnaire 
All patients were asked to complete a questionnaire on dental habits including tooth 
brushing frequency, use of mouthwash and floss, date of last routine dental examination, 
history of previous dental disease and tooth extraction and changes in the appearance of 
teeth and gums.  This is because a major risk factor for the development of periodontitis is 
having poor dental habits [109, 112], and thus it was important to be able to control for this 
as a potential confounder.   See Appendix 1 for questionnaire. 
 
 
2.10  Plasma hs-CRP ELISA 
Plasma hs-CRP was measured by ELISA using a commercially available kit (Cambridge 
BioScience, Cambridge, UK) as per manufacturer’s instructions.  Patient plasma samples 
were diluted 1:1000 with the provided sample diluent.  The prediluted standards were 
diluted further with sample diluent to achieve a 1:100 dilution.  100L of each standard and 
patient sample were added to each well of the plate in duplicate.  The wells were covered 
and incubated for 30minutes at room temperature.  One litre of washing solution was 
prepared by diluting 50ml of concentrated washing solution in 1000ml of distilled water. 
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Each well was washed 3 times with 300l of washing solution.  100l of chromagen solution 
was added to each well before a further incubation of 10minutes in a light protected 
environment. The reaction was stopped by adding 50l of stopping solution to each well and 
the absorbance was then read at 450nm using a microplate reader (Biotech Plate Reader, 
Synergy HT, Winooski, USA).  
The hs-CRP concentration in the samples was calculated by interpolation from the standard 
curve.  




2.11  Validation of CRP ELISA for saliva – Salimetrics and 
Abcam 
A spike and recovery experiment to measure CRP in saliva was conducted on a commercially 
available ELISA kit (Abcam, Cambridge, UK).  The manufacturers state the kit has been 
validated for measuring CRP in saliva.  Two saliva samples from different individuals were 
used for the experiment.  60mls of saliva was added to 3 separate Eppendorfs and to each 
Eppendorf, 60mls of a chosen standard was added.  The standards were prepared as per the 
manufacturers’ protocol.  50ul of standards, neat saliva and spiked saliva samples were 
added to the wells in duplicate.  The plate was covered and incubated for two hours.  
Washing buffer was produced by diluting 30mls of the supplied wash buffer with 570mls of 
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distilled water.  Each well was washed five times with 300ul of washing buffer.  50ul of 
prepared CRP antibody was added to each well and the plate incubated for a further 
30minutes.  Each well was again washed five times with 300ul of washing buffer.  50ul of 
prepared SP conjugate was added to each well and the plate incubated for a further 
30minutes.  Again, each well was washed five times with 300ul of washing buffer.  50ul of 
chromogen substrate was added to each well and incubated for 10minutes and the reaction 
then stopped by adding 50ul of stop solution to each well.  Absorbance was read at 450nm 
and 570nm using a microplate reader (Biotech Plate Reader, Synergy HT, Winooski, USA).  
The CRP concentration in the samples was calculated by interpolation from the standard 
curve.   The percentage recovery of the spiked sampled was determined using: 
 % recovery = (assay result for spiked sample/ (assay result for neat sample + amount 
spiked)) x 100. 
A further spike and recovery experiment to measure CRP in saliva was conducted on a 
different commercially available ELISA kit (Salimetrics Europe, Newmarket, UK).  The 
manufacturers state the kit has been validated for measuring CRP in saliva.  Two saliva 
samples from different individuals were used for the experiment.  Saliva samples were 
spiked with different amounts of the CRP standard and diluted with variable amounts of 
sample diluent to ensure the final saliva sample was diluted 1:10 as per manufacturers’ 





VOLUME OF SALIVA VOLUME OF 6000PG/mL CRP 
STANDARD 
VOLUME OF DILUENT 
15uL 75uL 60uL 
15uL 37.7uL 97.5uL 
15uL 18.75uL 116.25uL 
15uL 9.38uL 125.62uL 
15uL 4.69uL 130.31uL 
15uL 2.35uL 132.65uL 
15uL 0 135uL. 
Table 1: Volumes of saliva, standard and diluent used to create spiked samples for Salimetrics ELISA  
 
The standard curve was prepared as per manufacturers’ protocol. 50uL of standards and 
saliva samples were pipetted into wells in duplicate.  150uL of 1:250 diluted enzyme 
conjugate was added to each well. The plate was covered and incubated for 2hours on a 
rotatory shaker at 500rpm.  Washing buffer was created by diluting 50mL of washing buffer 
to 450mL distilled water.  Each well was washed four times with 300ul of washing buffer.  
200ul of TMB substrate was added to each well and the plate incubated on the rotary shaker 
at 500rpm in a light protected environment for a further 30minutes.  The reaction was 
stopped by adding 50ul of stop solution to each well and mixing on the rotary shaker for 
3minutes.   
Absorbance was read at 450nm and 630nm using a microplate reader (Biotech Plate Reader, 
Synergy HT, Winooski, USA).  
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The CRP concentration in the samples was calculated by interpolation from the standard 
curve.   The percentage recovery of the spiked sampled was determined using: 
% recovery = (assay result for spiked sample/ (assay result for neat sample + amount spiked)) 
x 100. 
The Salimetrics kit was subsequently validated for linearity of dilution.  The same technique 
was used as described above to prepare the standards and run the assay.  The saliva samples 
were diluted to the concentrations in Table 2 and the same dilutions also spiked with a 
known quantity of the top CRP standard of 3000pg/ml also as shown in Table 2.  The 

















3000pg/ml CRP (ul) 
VOLUME OF 
DILUENT (ul) 
1:2 75 0 75 
1:5 30 0 120 
1:10 15 0 135 
1:20 7.5 0 142.5 
1:50 3 0 147 
1:100 1.5 0 148.5 
1:2 plus spike 75 75 0 
1:5 plus spike 30 75 45 
1:10 plus spike 15 75 60 
1:20 plus spike 7.5 75 67.5 
1:50 plus spike 3 75 72 
1:100 plus spike 1.5 75 73.5 
Table 2: Volumes of saliva, standard and diluent used in the Salimetrics linearity of dilution validation. 
 
 
2.12  Plasma IL-8 ELISA 
Plasma IL-8 was measured by ELISA using a commercially available kit (R&D Systems Ltd, 
Abingdon, UK) as per manufacturer’s instructions.  100ul of assay diluent was added to each 
well.  The standards were prepared as per manufacturer’s instructions.  50ul of standards 
and plasma samples were added to the well and the plate was incubated for 2 hours.  Wash 
buffer was produced by adding 20ml of concentrated wash buffer to 480ml of distilled 
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water.  Each well was washed 4 times with 300ul of washing buffer.  100ul of IL-8 conjugate 
was added to each well and the plate incubated for a further 1 hour.  Each well was again 
washed 4 times with 300ul of washing buffer.  Colour reagents A and B were mixed together 
and 200ul of the mixed solution was added to each well and the plate incubated for 
30moiniutes in a light protected environment.  The reaction was stopped by adding 50ul of 
stop solution to each well. 
The absorbance was then read at 450nm and 630nm using a microplate reader (Biotech 
Plate Reader, Synergy HT, Winooski, USA).  
The IL-8 level in the samples was calculated by interpolation from the standard curve.  
The mean minimal detectable concentration was 3.5pg/ml as per the manufacturers product 
information leaftlet. 
 
2.13  Validation of IL-8 ELISA in saliva  
A spike and recovery experiment to measure IL-8 in saliva was conducted on a commercially 
available ELISA kit (R&D Systems Ltd, Abingdon, UK).  This kit had not been validated for use 
in saliva previously. 
Two saliva samples from different individuals were used for the experiment.  After thawing 
the samples, they were ultra-centrifuged at 29000rpm for 20minutes at 4°C and supernatant 
removed.  75mls of saliva supernatant was then added to 7 separate Eppendorfs and to this 
75mls of each standard was added and the mixture vortexed.  This was replicated for the 
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second saliva sample.  The assay was then run in the same manner as for plasma IL-8 per 
manufacturer’s instructions. 
The IL-8 in the samples was calculated by interpolation from the standard curve.   The 
percentage recovery of the spiked sampled was determined using: 
 % recovery = (assay result for spiked sample/ (assay result for neat sample + amount 
spiked)) x 100. 
The kit was subsequently validated for linearity of dilution.  The same technique was used as 
described above to prepare the standards and run the assay.  The saliva samples were 
diluted to 1:2, 1:10 and 1:50 and the same dilutions also spiked with a known quantity of IL-
8 standard of 2000pg/ml as shown in Table 3.  The recovery was determined in the same 






3000pg/ml CRP (ul) 
VOLUME OF 
DILUENT (ul) 
1:2 75 0 75 
1:10 15 0 135 
1:50 3 0 147 
1:2 plus spike 75 75 0 
1:10 plus spike 15 75 60 
1:50 plus spike 3 75 72 





2.14  Statistical Analysis 
Statistical analyses were performed using the SPSS statistical program (version 24.0 IBM, 
Chicago, USA). Data were tested for normality using the Shapiro-Wilk test and then the 
appropriate statistical test was used to compare groups.   
Parametric data was analysed using student’s t-test and non-parametric data by Mann 
Whitney U Test.  Chi square, Cochran’s Q and Kendall’s tau-b tests were used to assess for 
differences across groups and binary logistic regression models were used to calculate odds 
ratios (see results).  Spearman’s rank testing was used to assess correlations of non-
parametric data.  2-tailed p values are quoted throughout the results and a p value <0.05 












Studies have suggested mechanistic associations between COPD and periodontitis (that of 
increased neutrophilic inflammation), but many COPD patients have known confounding 
factors for the development of periodontitis such as advancing age, smoking, poor dental 
habits and lower socioeconomic status. Here AATD provides a useful model of study since 
patients have often smoked less and are younger.  Data regarding dental habits or socio-
economic grouping are not usually available in many studies. 
To test the hypothesis in section 1.81 and the aim in section 1.91, we describe the 
prevalence and severity of periodontitis in a cohort of patients with AATD and non-AATD 
COPD using several recognised definitions of periodontitis.  We then compare the 
prevalence and severity of periodontitis to parameters of lung disease severity, both with 
and without correcting for potentially confounding risk factors for periodontitis.   
 
3.1.2 Patients, Clinical Review and Questionnaires 
This study included 88 dentate (presence of ≥1 natural tooth) non-deficient COPD patients 
recruited from the Chronic Disease Resource Centre (CDRC) and 68 dentate AATD patients 
recruited from the Antitrypsin Deficiency Assessment and Programme for Treatment 
(ADAPT) cohort at Queen Elizabeth Hospital Birmingham, between 2014 and 2016.   
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Clinical data gathering, questionnaire responses and dental assessments occurred as 
described in Chapter 2. 
 
3.1.3 Statistical analysis 
Data analysis was performed using SPSS computer package version 24. 
All continuous data is presented as mean and standard deviation. Parametric data was 
analysed by student’s paired t-test and non -parametric data by Mann Whitney U-test. 
Binary data is presented as numbers and percentage of the total.  Categorical data is 
presented as median with range where appropriate.  Categorical data is analysed by Chi 
square and Kendall’s tau-b tests. 
 
3.1.4 Results 
The baseline demographics and socio-economic data for the non-deficient COPD and AATD 









Variable Non-deficient COPD AATD p-value 
 Total n 
included. 
 Total n 
included. 
  
Male n. (%) 88 62 (70.5%) 68 39 (57.4%) 0.09 
Age years (SD) 88 68.6 (7.6) 68 54.6 (12.5) <0.001 
BMI (SD) 88 27.8 (6.2) 68 26.0 (5.1) 0.06 
Current smoker n. (%) 88 21 (23.9%) 68 1 (1.5%) <0.001 
Ex-smoker n. (%) 88 67 (76.1%) 68 42 (61.8%) 0.052 
Never smoker n. (%) 88 0 (0%) 68 25 (36.7%) <0.001 
Average smoking PYH of current 
and ex-smokers (SD) 
88 56.0 (42.4) 43 19.9 (21.1) <0.001 
Diabetes n. (%) 88 9 (10.2%) 68 1 (1.5%) 0.044 
Hypertension n. (%) 88 22 (25%) 68 9 (13.2%) 0.068 
Vascular disease n. (%) 88 26 (29.5%) 68 1 (1.5%) <0.001 
Median IMD Quintile (range) 88 5 (3-5) 65 2 (1-4) <0.001 
Average age leaving education – 
years (SD) 
72 15.7 (2.5) 54 18.6 (3.6) <0.001 
Median Highest Qualification 
Obtained (range) 
70 1 (1) 55 2 (2-4) <0.001 
Median NS-SEC score (range) 69 5 (4-5) 52 2 (2-4) <0.001 
Median household income 54 2 (1-2) 48 3 (2-4) <0.001 
Table 4 4: Demographic and socio-economic data for non-deficient COPD and AATD groups. 
Legend: Data are presented as mean with corresponding standard deviation or median and range 
depending on the type of data.  Significant results are in bold.  PYH= smoking pack year history, 
vascular disease = any history of peripheral vascular disease, ischaemic heart disease, 
cerebrovascular disease, IMD=index of multiple deprivation; a score of deprivation based on postcode 
[214], Highest Qualification Codes; 0=none, 1= GCSE, 3= A-level, 4=degree, 5=post-graduate 
qualification, NS-SEC = National Statistics Socio-economic Classification; the primary social 
classification system used in UK based on occupation; 1=Higher management, 2= Lower managerial, 
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administrative and professional occupations, 3= Intermediate occupations, 4= Small employers and 
own account workers, 5= Lower supervisory and technical occupations, 6= Semi-routine occupations, 
7= Routine occupations [215].   Household Income Codes; 1=0-10k, 2=10-20k, 3=20-40k, 4=40-80k, 
5=>80k.  Statistical tests used; Mann-Whitney U test for non-parametric data, Chi Square test for 
nominal categorical data and Kendall’s tau b test for ordinal data. 
 
The lung function and symptom burden results for the non-deficient COPD and AATD groups 
are shown in Table 5.  
Variable Non-deficient COPD AATD p-value 
 Total n 
included. 
 Total n 
included. 
  
Median mMRC (range) 88 3 (2-4) 68 2 (2-4) <0.001 
Exacerbation Frequency (SD) 87 2.8 (3.0) 68 1.2 (1.2) <0.001 
Bronchitis n. (%) 87 37 (42.5) 68 24 (35.3) 0.360 
Use of ICS n. (%) 87 74 (85.1) 68 36 (52.9) <0.001 
Use of LAMA n. (%) 88 73 (83.0) 68 40 (58.8) 0.001 
Use of long acting β-2 agonist 
n. (%) 
88 74 (84.1) 68 37 (54.4) <0.001 
Use of short acting β-2 
agonist n. (%) 
88 79 (89.8) 68 34 (50%) <0.001 
FEV1: FVC ratio (SD) 86 46.7(15.9) 68 50.9(16.5) 0.096 





Median GOLD stage of 
patients with COPD (range) 
76 3 (2-3) 57 2 (2-3) 0.113 










Radiological emphysema n. 
(%) 
76 58 (76.3) 63  49 (77.8) 0.838 
Table 5: Lung function and symptom burden for non-deficient COPD and AATD groups. 
50 
 
Legend: Data are presented as mean with corresponding standard deviation unless otherwise stated. 
Significant results are in bold.  mMRC = modified Medical Research Council scale ICS = inhaled 
corticosteroid, LAMA= long acting muscarinic antagonist.  Statistical tests used; Mann-Whitney U test 
for non-parametric data, Chi Square test for nominal categorical data and Kendall’s tau b test for 
ordinal data. 
The dental habits and symptoms results for the non-deficient COPD and AATD groups are 
shown in Table 6. 
Variable Non-deficient COPD AATD p-value 
 Total n 
included. 
 Total n 
included. 
  
No. of teeth (SD) 85 17 (7.5) 68 24 (5.4) <0.001 
Twice daily tooth brushing n. (%) 75 35 (46.7) 65 47 (72.3) 0.001 
Regular use of mouthwash n. (%) 75 38 (50.7) 65 20 (30.8) 0.017 
Regular use of floss n. (%) 75 13 (17.3) 65 38.2 (40.0) 0.003 
Last dental examination ≤6months 
n. (%) 
75 48 (64.0) 65 41 (63.1) 0.172 
Previous dental disease n. (%) 75 17 (22.7) 64 13 (20.3) 0.737 
Appearance of loss of bone n. (%) 75 9 (12.2) 64 8 (12.5) 0.952 
Wider spaces between teeth n (%) 75 30 (40.0) 65 13 (20) 0.011 
Teeth appear longer n. (%) 75 29 (38.7) 63 34 (54.0) 0.072 
Painful teeth/ gums n. (%) 75 11 (14.7) 64 18 (28.1) 0.052 
Bleeding gums n. (%) 75 19 (25.3) 65 37 (56.9) <0.001 
Previous tooth extraction n. (%) 74 13 (17.6) 65 7 (10.8) 0.255 
Table 6: Dental symptoms and habits for non-deficient COPD and AATD groups 
51 
 
Legend: Data are presented as mean with corresponding standard deviation unless otherwise stated. 
Significant differences are in bold.  Statistical tests used; Mann-Whitney U test for non-parametric 
data, Chi Square test for nominal categorical data and Kendall’s tau b test for ordinal data.   
 
3.1.5 Summary of patient demographics 
Non-deficient COPD patients were older, more likely to be current or ex-smokers, had a 
greater smoking pack year history, used more inhaled therapy, had more severe COPD as 
defined by FEV1 and measures of gas transfer and a greater incidence of diabetes and 
vascular disease.  The non-deficient group were also of a poorer socio-economic status, had 
lower income and were less well educated than the AATD patients in keeping with reported 
differences to a healthy population [86, 91, 92].    
Non-deficient COPD patients had fewer teeth, reduced brush frequency and use of dental 
floss, although they reported use of mouthwash more than AATD patients. In keeping with 
this, several other studies have also shown COPD patients have significantly reduced brush 
frequency [83, 85, 87] compared to the general population.   There was no significant 
difference in attendance at dental visits or history of previous dental disease or tooth 
extraction.  However, non-deficient COPD patient were more likely to report that the space 
between their teeth appeared wider, whilst the AATD group reported more bleeding of 
gums on brushing.  There were no significant differences in any of the other dental 
symptoms or behaviours on the questionnaire. 
This in detail characterisation is essential to establish and account for any potential 
confounding factors for subsequent comparisons.  
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3.2 Prevalence of Periodontitis 
Definitions of periodontitis were chosen to reflect  periodontal measurements reported  
frequently in the current literature which can  vary from ≥2mm for CAL and ≥3mm for PPD 
[81].  However low values may over represent disease [216] and therefore we chose 
thresholds beyond the normal ranges to exclude the risk of including healthy periodontium.   
The following definitions were used;  
1) Average whole mouth PPD ≥ 4mm, 
2) Average whole mouth CAL ≥4mm 
3) PD ≥4mm at any one tooth 
4) CAL ≥ 4mm at any one tooth 
5) The Centers for Disease Control and Prevention  - American Association of 
Periodontology (CDC-AAP) criteria [97] as described in section 1.3.2.  




The prevalence of periodontitis varied depending on the definition used.  It ranged from 
0.7% to 93.5% in the combined cohorts, 1.2 – 97.6% in non-deficient COPD and 0 – 88.2% in 





DEFINITION WHOLE GROUP COPD AATD 
Av PPD ≥4mm n. (%) 1 (0.7) 1 (1.2) 0 
Av CAL ≥4mm n. (%) 32 (20.9) 29 (34.1) *** 3 (4.4) 
Max PPD ≥4mm n. (%) 124(81.0) 72 (84.7)  52 (76.5) 
Max CAL ≥4mm n. (%) 143 (93.5) 83 (97.6) * 60 (88.2) 
CDC-AAP n. (%) 127 (83) 78 (91.8) ** 49 (72.1) 
BPE n. (%) 124 (81) 72 (84.7) 52 (76.5) 
Table 7: Prevalence of periodontitis according to definition used.   
Legend:  Data is presented as number of patients affected and corresponding percentage of the 
group.  Statistical tests used; Chi Square Test and Fishers Exact Test.  Statistically significant 
differences between COPD and AATD are denoted by *** = p<0.001, ** = p<0.01 and * = p<0.05. 
Cochran’s Q test confirmed a statistically significant difference in the prevalence of 
periodontitis depending on the definition used.  This was true for the whole group and the 
subgroups of non-deficient COPD and AATD patients, p<0.001 for all tests. 
With the exception of average and maximum PPD ≥4mm and periodontitis by BPE criteria; 
non-deficient COPD patients had a significantly higher prevalence of periodontitis compared 
to those with AATD.  For maximum CAL ≥4mm at any tooth, χ2 = 5.5, p<0.05; average CAL 
≥4mm, χ2 = 20.2; p<0.001, and for CDC-AAP criteria, χ2 = 10.4; p<0.01. 
In comparison to the prevalence of pathological periodontal pockets in the 2009 ADHS 
(45%), both non-deficient COPD group and AATD group had increased prevalence (84.7 and 
76.5% respectively).  This was statistically significant for non-deficient COPD; χ2 = 53.3, 
p<0.001 and for AATD χ2 = 26.9, p<0.001. 
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A statistically significant difference existed between the groups when assessing periodontitis 
severity according to CDC-AAP criteria.  7% of non-deficient COPD patients had no 
periodontitis and 2.4%, 47% and 43% had mild, moderate and severe disease respectively.  
In AATD, 28% of patients had no periodontitis, 50% and 22% had moderate and severe 
disease respectively and they were more likely to have no or less evidence of severe 
periodontitis, (τb = 0.27, p<0.001) than patients with non-deficient COPD.  A similar pattern 
was seen when periodontitis severity was scored using BPE criteria with AATD patients less 
likely to have a score of 4 on the BPE, (τb = -0.17, p<0.05). 
To measure the association between periodontitis and COPD, binary logistic regression was 
used to determine the odds ratio (OR) for the non-deficient COPD group compared to AATD 
and this is summarised in Table 8.  A result for average PD ≥4mm was not statistically 
possible as only 1 patient fulfilled this criterion.  The results show three of the definitions 




ODDS RATIO FOR 
NON-DEFICIENT 
COPD PATIENTS 
   95% CI P-VALUE 
Average CAL ≥4mm           11.2   3.2-38.3 <0.001 
Maximum CAL ≥4m             5.5   1.1-27.0 <0.05 
Maximum PPD ≥4mm             1.7   0.8-3.8- NS 
CDC-AAP criteria             4.3   1.6-11.0 <0.01 
BPE criteria              1.7   0.8-3.9 NS 






Legend: Statistical tests used; Binary logistic regression was used to assess the OR for each binary 
outcome measure (periodontitis definition) individually.  Significant results are shown in bold. 
 
This univariate analysis supports an increased association between non-deficient COPD and 
periodontitis when compared to AATD patients for some of the periodontitis definitions.  
However, as there was a significant difference in age and smoking history between the COPD 
and AATD groups, and as these variables are also associated with periodontitis, they were 
included in a further regression model.  After adjusting for these variables, only average CAL 
≥4mm remained significantly associated with the non-deficient COPD group but with 
reduced OR of 7.9, 95% CI 1.8-35.5; p<0.01 (Table 9). For this reason, average CAL ≥4mm 
was chosen for the later comparisons as this was the only periodontal measurement that 
remained a significant predictor for non-deficient COPD and AATD after correcting for risk 
factors common to both periodontitis and chronic lung disease.  The associations with the 
other periodontal measurements such as PPD could be attributed to confounding variables 
such as age and smoking, whereas the regression models show these confounders did not 
fully explain the association with Average CAL 4mm and lung disease.  Therefore, it was felt 
this was more likely to be representative of a genuine predictor of periodontitis in the COPD 







ODDS RATIO FOR 
NON-DEFICIENT 
COPD PATIENTS 
   95% CI P-VALUE 
Average CAL >4mm 
Adjusting for age & PYH 
            7.9   1.8-35.4 
 
0.007 
Maximum CAL >4m 
Adjusting for age & PYH 




Adjusting for PYH 
            1.3   0.5-3.4 
 
NS 
Table 9: Adjusted OR for periodontitis in the non-deficient COPD patient group in comparison to AATD 
group. 
Legend: Statistical tests used: Binary logistic regression was used to assess the OR for each binary 
outcome measure (periodontitis definition) individually after adjustment for confounders.  
Significant results are shown in bold. 
Previous univariate analyses confirmed other variables as important risk factors for non-
deficient COPD. These included IMD score, age when leaving education, highest educational 
qualification, NS-SEC score, presence of vascular disease, use of inhaled corticosteroids, 
SABA, LABA and LAMA and brushing teeth less than twice daily.  Limited sample size 
prevented statistical correction for all potential confounders in a standard regression model 
so additional binary logistic regression models were used to assess the contribution of these 
variables to the prevalence of periodontitis in the non-deficient COPD compared to AATD 
group defined by average CAL ≥4mm.   As four of these variables (IMD score, age when 
leaving education, highest qualification gained, NS-SEC score) are also surrogate markers for 




VARIABLES ADDED TO 
MODEL 
ODDS RATIO FOR NON-
DEFICIENT COPD 
PATIENTS 
95% CI P-VALUE 
IMD Quintile 
Vascular Disease 
7.5 1.49-38.1 0.015 
IMD Quintile 
ICS Use 
8.0 1.70-37.8 0.009 
IMD Quintile 
Tooth Brushing 
11.2 1.8-70.2 0.01 
IMD Quintile 
SABA 
9.8 2.1-47.2 0.004 
IMD Quintile 
LABA 
7.8 1.6-37.4 0.010 
IMD Quintile 
LAMA 
8.6 1.8-40.8 0.007 
Vascular Disease 
ICS Use 
7.5 2.0-27.6 0.003 
Vascular Disease 
Tooth Brushing 
7.4 2.0-28.0 0.003 
Vascular Disease 
SABA 
10.8 2.6-44.4 0.001 
Vascular Disease 
LABA 
11.0 2.8-43.0 0.001 
Vascular Disease 
LAMA 
12.2 3.1-48.2 <0.001 
ICS Use 
Tooth Brushing 
7.3 2.0-26.6 0.002 
ICS Use 
SABA 
10.8 2.7-42.9 0.001 
ICS Use 
LABA 
9.2 2.6-33.1 0.001 
ICS Use 
LAMA 
9.0 2.5-32.3 0.001 
SABA 
LAMA 
12.2 3.1-48.2 <0.001 
SABA 
LABA 
11.0 2.8-43.0 0.001 
LAMA 
LABA 
9.3 2.9-32.9 0.001 
Table 10: Adjusted OR for patients with non-deficient COPD having periodontitis compared to AATD 
Legend: IMD=index of multiple deprivation; a score of deprivation based on postcode [214], ICS = 
inhaled corticosteroid use, SABA= short acting β-2 agonist, LABA= long acting β-2 agonist, LAMA= 
long acting muscarinic antagonist.  Statistical tests used; Binary logistic regression.  Significant results 
are shown in bold. 
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Table 10 shows the adjusted OR when these variables are added to the model.  This 
confirmed that poorer socio-economic status, use of inhaled therapies, presence of vascular 
disease and reduced tooth brushing frequency in non-deficient COPD all contribute to, but 
do not fully explain the increased prevalence of periodontitis in non-deficient COPD 
compared to AATD. 
 
3.2.2 Summary of periodontal prevalence and association with AATD and non-
AATD COPD  
Prevalence ranged from 1.2-97.6% for non-deficient COPD and 0-88.2% for AATD patients.  
The prevalence for the general population in the UK (adults over the age of 16years) has 
been reported as 45% using PPD ≥4mm [101], although this increases to more than 70% 
when the age group is greater than 55years.  Thus, both the non-deficient COPD group and 
the AATD group had a significantly higher prevalence than seen in the general UK population 
(84.7% and 76.5 % versus 45%) when applying the same threshold for diagnosis. 
For most definitions, there was greater prevalence of periodontitis in non-deficient COPD 
compared to AATD patients (p<0.001).   After correction for age and smoking, only average 
CAL ≥4mm still had a greater prevalence in the non-deficient COPD group.   The non-
deficient COPD patients were of a poorer socio-economic status, had lower income and 
were less well educated than AATD patients. Regression analyses confirmed these variables 
contributed to the association between periodontitis in non-deficient COPD compared to 
AATD in this analysis.  Other common risk factors such as age, smoking history, 
socioeconomic status, vascular disease, use of inhaled therapy and poor dental habits were 
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also associated with periodontitis but did not fully account for the increased prevalence seen 
in the non-deficient COPD group compared to AATD.   
 
3.3 Periodontal Measurements and Respiratory Physiology 
No correlation of periodontal indices with parameters of lung function was seen in the non-
deficient COPD group, although there were significant negative correlations for AATD 
patients. The results are shown in Table 11.  Results for FEV1: FVC ratio and average CAL 














 AATD COPD 
VARIABLE rs p-value rs p-value 
Average CAL (mm)  
FEV1: FVC ratio 
 
-0.331 0.006 -0.411 <0.001 
























Maximum CAL (mm)  
FEV1: FVC ratio 
 
-0.149 0.225 -0.305 0.005 
























Average PPD (mm)  
FEV1: FVC ratio 
 
-0.171 0.162 -0.181 0.102 
























Maximum PPD (mm)  
FEV1: FVC ratio 
 
-0.109 0.376 -0.226 0.040 
























Table 11: Spearman’s rank correlations for periodontal indices and lung function parameters.  Significant 














Figure 2: Correlation between Average CAL (mm) and Percent of predicted FEV1 for AATD patients 
Legend: 68 patients, each data mark represents one patient.  Spearman’s Rho shows moderate 
correlation; rs -0.331, p<0.01. 
 















































Average CAL (mm) 
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Legend: 83 patients, each data mark represents one patient.  Spearman’s Rho shows moderate 




Figure 4: Correlation between Average CAL (mm) and Percent of TLCO for AATD patients. 
Legend: 68 patients, each data mark represents one patient.  Spearman’s Rho shows moderate 
correlation; rs -0.361, p<0.01. 
 
 
3.3.1 Summary of lung physiology  
Moderate correlations were seen for measures of airway obstruction in both non-deficient 
COPD and AATD patients and clinical attachment level.  Weak to moderate correlations were 
seen in the AATD patients for measurements of gas transfer and some periodontal indices. 



















Average CAL (mm) 
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could relate to the enhanced inflammatory processes seen in AATD.  This will be explored in 
the next chapter. 
 
 
3.4  VALIDATION OF ELISA KITS FOR USE IN SALIVA 
3.4.1 Introduction 
It is the policy of this research unit to perform in house validation of any ELISA kits not used 
previously within this department. Spike and recovery validation was performed for two 
commercially available ELISA kits which manufacturers claim are valid for the measurement 
of CRP in saliva, Abcam (Cambridge, UK) and Salimetrics (Europe, Newmarket, UK) and for an 
ELISA kit designed to measure plasma/ serum levels of IL-8 for use in saliva, R&D Systems, 
(Abingdon, UK). 
 
3.4.2 Saliva Sampling and Methods 





A standard curve was generated for the Abcam kit (reference number ab108826) as shown 




Figure 5: Standard Curve obtained from Abcam CRP ELISA kit ab108826 following manufacturer instructions 
 
Saliva was collected from two non-smoking individuals at Queen Elizabeth Hospital 
Birmingham, with ethical approval from the National Research Ethics Service 
(REC13/WM/0044) as part of a larger study investigating inflammation in periodontitis and 
chronic lung disease. Participant One had psoriasis, which has been associated with higher 
concentrations of salivary CRP and Participant Two was a sex and age matched healthy 
control.  These subjects were chosen for initial validation as they were thought to be likely to 
produce samples with higher and lower concentrations of CRP respectively, thus reflecting 
the ranges described in health and disease.    
Three spiking concentrations were chosen, 0.25ng/ml, 2 ng/ml and 16ng/ml, as these 
represented the lowest, middle and highest standard for the assay.   
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Participant One’s saliva sample had a reported mean concentration of CRP of 6.03ng/ml, 
which fell within the standard curve, and the CV of duplicate measurements was 4%.  
Participant Two’s saliva sample had a reported mean concentration of CRP of 0.07ng/ml, 
below the lower limit of detection quoted for the assay and at these low concentrations, the 
CV of duplicate measurements obtained by interpolation from the standard curve was 30%.  
For Participant One, recovery of the spike ranged from 59-144%, with the most inaccurate 
recovery seen at the lower and higher concentrations of spike.  For participant two, the 
spiked recovery was 5-28% and a value was not obtained for the neat plus 0.25ng/ml spike 
as the optical density reading for this sample was less than the optical density obtained for 
zero on the standard curve. See Figure 5. 
 
As spike and recovery did not fall within acceptable criteria, no further attempts were made 





Figure 5: Graphical representation of the results of the spike and recovery experiment for Abcam CRP ELISA 
kit. 
 
Legend: Horizontal lines indicate percentage of recovery considered acceptable for the kit to be valid 
(80-120%).  Sample 1+16 = saliva sample 1 spiked with a known quantity of the 16ng/ml standard 
provided in the ELISA kit.  Sample 1+2 = saliva sample 1 spiked with a known quantity of the 16ng/ml 
standard provided in the ELISA kit.  Sample 1+0.25 saliva sample 1 spiked with a known quantity of 
the 16ng/ml standard provided in the ELISA kit.  Sample 2 = saliva sample 2, spiked in the same way 
as sample 1.  A result was not possible for Sample 2 +0.25. 
Abcam subsequently confirmed that the kit had not been validated for use in saliva by the 
























The same samples were used to validate the Salimetrics kit for use in saliva.  Again, a 
suitable standard curve was generated (see figure 6).  Using these samples, Participant 1 had 
mean CRP concentrations of 2384.6 pg/ml with an intra-measurement CV of 4.35% and 
Participant 2 had a mean CRP concentration of 295.77 pg/ml with an intra-measurement CV 
of 3.54%.  Spiking was performed for all standards and recovery fell into recommended 
acceptability criteria, with the percentage of recovery obtained being between 80-111%, 
shown in Figure 7. 
 
 




























Figure 7: Graphical representation of the results of the Spike and Recovery validation experiment for 
Salimetrics CRP ELISA 
Legend: Horizontal lines indicate percentage of recovery considered acceptable for the kit to be valid 
(80-120%).  Sample 1+3000 = saliva sample 1 spiked with a known quantity of the 3000pg/ml 
standard provided in the ELISA kit.  Sample 1+1500 = saliva sample 1 spiked with a known quantity of 
the 1500pg/ml standard provided in the ELISA kit and so forth.  Sample 2 = saliva sample 2, spiked in 
the same way as sample 1.   
 
A linearity of dilution experiment was also performed which confirmed the kit produced 
valid results at dilutions of 1:2, 1:5, 1:10, 1:20, 1:50, 1:100 with recovery of 92-99%, shown 



















Figure 8: Graphical representation of the results of the linearity of dilution validation experiment for 
Salimetrics CRP ELISA. 
Legend: Horizontal lines indicate percentage of recovery considered acceptable for the kit to be valid 
(80-120%).   Inter-plate assay variation on patient samples was 12.8%. 
 
3.4.3.3 IL-8 
We successfully validated the R&D kit for use in measurement of IL-8 in saliva.   
A suitable standard curve was generated (see figure 9).  The test sample had median IL-8 
level of 1801.44 pg/ml with an intra-measurement CV of 1.80%.  Spike and recovery was 
performed for this sample and recovery fell into recommended acceptability criteria 






















Figure 9: Standard Curve obtained from R&D IL-8 ELISA kit following manufacturer instructions 
 
Figure 10: Graphical representation of the results of the Spike and Recovery validation experiment for R&D IL-
8 ELISA 
Legend: Horizontal lines indicate percentage of recovery considered acceptable for the kit to be valid 
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provided in the ELISA kit.  Sample +1000 = saliva sample spiked with a known quantity of the 
1000pg/ml standard provided in the ELISA kit and so forth.   
A linearity of dilution experiment was also performed which confirmed the kit produced 
valid results at dilutions of 1:2 and 1:10 with recovery of 85-118%, shown in Figure 11.  At 
saliva dilution of 1:50 the recovery was less than 80% for one sample and thus concluded not 
validated at this dilution factor.  
 
Figure 11: Graphical representation of the results of the linearity of dilution validation experiment for R&D 
IL-8 ELISA 
Legend: Horizontal lines indicate percentage of recovery considered acceptable for the kit to be valid 
(80-120%).  Sample A 1:10 = saliva sample A diluted 1:10 and so forth.  Sample A Spike 1:2 = saliva 
sample A diluted 1:10 and spiked with a known quantity of the 2000pg/ml standard provided in the 


















































Following the validation experiments, the Salimetrics CRP kit was used to measure CRP in 
saliva and the R&D kit for IL-8 in saliva.  All saliva samples were initially run “neat” and those 
that required dilution as the initial assay result was off the top of the curve were re-run at a 
dilution of 1:10 for both CRP and IL-8. 
 
 
3.5  MARKERS OF INFLAMMATION 
 
3.5.1 Introduction 
To examine inflammatory associations between respiratory disease and periodontitis we 
analysed the concentrations of CRP and IL-8 both in the peripheral circulation and in saliva.   
 
3.5.2 Patients 
The same patients whose data was used in the previous results chapters were used for this 
analysis and their basic demographics were similar to that of the whole cohort detailed 
earlier.  Details are provided in section 2.2.  Plasma hs-CRP results were obtained in 46 
dentate COPD patients and 40 dentate AATD patients.  Plasma IL-8 results were obtained in 
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47 dentate COPD patients and 42 dentate AATD patients.  Salivary samples were obtained in 
84 dentate COPD patients and 66 dentate AATD patients.  Data is not available for the whole 
cohort due to a lack of obtaining blood samples at the same time as dental sampling, and in 
some cases, dental samples were insufficient for testing.  However, this smaller sub-group 
does not significantly differ in the characteristics already outlined for the main group. 
 
3.5.3 Blood and Saliva Sampling 
This is described in sections 2.4 and 2.5 
 
3.5.4 ELISA analysis 
This is described in section 2.6  
 
3.5.5 Statistical Analysis 
Non-parametric data was analysed by Mann Whitney U tests and Spearman’s rank 
correlation and, parametric data by student’s t-test and Pearson’s correlation coefficient.   
 
3.5.6 Results 
Plasma hs-CRP was above the lower limit of detection for all samples tested.  The mean (SD) 
hs-CRP level in COPD patients was higher (5.81(3.55) ug/ml) than in AATD patients (1.99 
(3.02) ug/ml) p<0.001.  
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Plasma IL-8 was above the lower limit of detection for 76.4% of samples tested, but was 
more often detectable in COPD patients, n=44 (93.6%) than AATD n=24 (57.1%), p<0.001.  
The mean IL-8 levels in detectable samples were similar in COPD patients; 5.08 (4.10) pg/ml 
and in AATD patients; 4.59 (4.46) pg/ml, p=ns, however, the reported lower level of 
quantification for this assay is 31.3 pg/ml and therefore further analysis of plasma IL-8 
results could not be performed as all results fell below this level. 
Using the validated kit, salivary CRP was detectable in 100% of samples tested.  18 samples 
initially produced assay results which were off the top of the standard curve for the ELISA 
kit.  These samples were subsequently diluted 1:100 however 2 samples were still above the 
top of the curve and were excluded from analysis.  5 diluted samples produced assay results 
with a CV >20% and were also excluded from analysis. Thus, salivary CRP results were 
analysed for 81 COPD and 62 AATD patients.  
The mean (SD) salivary CRP in COPD patients was higher; 1240.43 (3368.57) pg/ml than in 
AATD patients; 703.93 (1549.76) pg/ml, p<0.05. 
A significant positive relationship between plasma hs-CRP and salivary CRP was seen; 
Spearman’s Rho 0.391, p<0.001, (see Figure 12); but when the groups were analysed 




Figure 12: Association between salivary CRP and plasma hs-CRP for all patients 
Legend: 78 patients, each data mark represents one patient.  Spearman’s Rho shows moderate 
correlation; rs 0.391, p<0.01. 
 
Using the validated kit, salivary IL-8 was detectable in 100% of samples tested.  2 samples 
are not included in further analysis as 1 fell below the bottom of the standard curve and the 
other was off the top of the standard curve despite dilution 1:10. Thus, salivary IL-8 results 
were analysed for 82 COPD and 66 AATD patients.  
The mean (SD) salivary IL-8 in COPD patients and AATD was similar; 1821.55 (3170.48) pg/ml 
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Moderately positive correlations were seen between salivary CRP and salivary IL-8 for COPD 
patients, rs 0.367, p=0.001 and for AATD patients, rs 0.391, p=0.001, see Figure 13. 
 
Figure 13: Association between salivary CRP and salivary IL-8  
Legend: 79 COPD patients and 62 AATD patients. Each data mark represents one patient.  
Spearman’s Rho shows moderate correlation; rs 0.367, p=0.001 for COPD and rs 0.391, p=0.001 for 
AATD patients. 
 
3.5.6.1 Demographics and Socioeconomic Status 
No significant associations were seen for plasma hs-CRP, salivary CRP or salivary IL-8 and 
gender, age, smoking status or pack year history, co-morbid presence of diabetes mellitus, 
hypertension or vascular disease, age at leaving education, NS-SEC score or annual 






















Plasma hs-CRP was significantly positively correlated with BMI in AATD patients; rs 0.331, 
p=0.037, and IMD quintile in AATD patients, rs 0.347, p=0.035, but neither was associated 
with COPD patients. 
A weakly positive correlation was seen in the COPD group for salivary IL-8 and highest 
qualification gained; rs 0.271, p=0.029 but not for AATD and no relationship was seen for 
salivary CRP. 
 
3.5.6.2 Respiratory Disease & Lung Function 
No significant associations were seen for plasma hs-CRP, salivary CRP or salivary IL-8 and 
GOLD stage of COPD severity, exacerbation frequency, presence of bronchitis, radiological 
evidence of emphysema, use of inhaled corticosteroid, SABA, LABA, LAMA or any lung 
function parameter. 
Salivary CRP was positively correlated with mMRC score for COPD patients, rs 0.328, p<0.01, 
and AATD patients, rs 0.308, p<0.05, see Figure 14, but no association was seen for plasma 




Figure 14: Association between salivary CRP and mMRC score.  
Legend: 80 COPD patients and 62 AATD patients. Each data mark represents one patient.  
Spearman’s Rho shows moderate correlation for COPD patients, rs 0.328, p<0.01, and AATD patients, 
rs 0.308, p<0.05, 
 
3.5.6.3 Dental Habits & Symptoms 
No significant associations were seen for plasma hs-CRP, salivary CRP or salivary IL-8 and no. 
of teeth, frequency of tooth brushing, use of mouthwash or dental floss, last dental 
examination, previous dental disease, appearance of loss of bone, wider spaces between 
teeth, bleeding gums, loose teeth or previous dental extractions.  
Salivary IL-8 was significantly associated with patients reporting an appearance of longer 
teeth in the COPD group only; Mann Whitney U 353.0, p=0.006, and with painful teeth and 























Plasma hs-CRP and salivary IL-8 did not correlate with any of the periodontal measurements 
undertaken. 
For COPD patients, there was a significant difference in plasma hs-CRP and diagnosis of 
periodontitis by maximum probing depth ≥4mm at any tooth and therefore also BPE score; 
5.45 +/- 3.56 vs 8.75 +/- 1.87 ug/ml, with patients with periodontitis by these definitions 
having lower plasma hs-CRP than those who were disease free, p=0.034.  No other 
significant results were found for the other diagnoses of periodontitis applied. 
Salivary CRP positively correlated with maximum probing depth (mm) for AATD patients 
only, Spearman’s Rho 0.254, p<0.05 and therefore was also significantly associated with a 
diagnosis of periodontitis determined by PPD ≥4mm, p0.05 and BPE, p<0.05 for this group of 
patients. 

















4.1 Prevalence of periodontitis in COPD and AATD 
 
The prevalence of periodontitis in non-deficient COPD and AATD in this study shows 
variation depending on the diagnostic criteria used.   Combined group prevalence ranged 
from 0.7-93.5% and was 1.2-97.6% for non-deficient COPD and 0-88.2% for AATD patients.  
The prevalence for the general population in the UK has been calculated from data from The 
Adult Dental Health Survey (ADHS) 2009 and reported as 45% using PD ≥4mm [101].  Both 
the non-deficient COPD group and the AATD group in this study had a significantly higher 
prevalence than this (84.7% and 76.5 % versus 45%) when applying the same threshold for 
diagnosis.     
For most definitions, there was greater prevalence of periodontitis in non-deficient COPD 
compared to AATD patients (p<0.001).   This is in keeping with previous studies reporting 
relationships between COPD and periodontitis [86, 92, 93, 145] but the current study is the 
first to compare prevalence in non-deficient COPD and AATD.   
Although the American Association of Periodontology has clear criteria [97], these are not 
always utilised in all epidemiological studies and previous studies have used varying 
combinations of periodontal measurements [82-88, 90-94] with no consistency or 
justification for measurements used.    There have been many diagnostic and classification 
systems developed [79-81, 95, 96] to help define periodontitis, however, none of these 
systems are used in routine practise and all have some flaws.   Thus in 2003, the Division of 
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Oral health at the Centres for Disease Control and Prevention in collaboration with the 
American Academy of Periodontology (CDC-AAP) appointed  a working group to develop a 
standardised case definition for periodontitis [79].  Use of the CDC-AAP definition found a 
greater prevalence (91.8 versus 72.1%, p<0.01) and severity (43% versus 22% severe 
periodontitis, p<0.001) in our non-deficient COPD cohort compared to AATD patients.  
However, this algorithm is primarily used in American research, whereas the Basic 
Periodontal Examination (BPE) recommended by The British Society of Periodontology is 
applied in clinical practice [100] and used routinely in the UK.  When BPE criteria were 
applied to the two cohorts, there was no difference in prevalence between the AATD and 
non-deficient COPD cohorts, although the latter group was still more likely to have more 
severe periodontal disease (27.1 versus 13.2%, p<0.05).   
The variation in results may, in part, be explained by the fact that PPD is considered a 
reflection of current disease status, whilst CAL represents cumulative disease [94].  In 
younger populations, PD and CAL correlate well, but gingival recession and therefore 
attachment loss is a normal part of the ageing process.  Increased PPD can also be seen in 
conditions other than periodontitis, and conversely periodontitis can exist without 
significant pockets, if gingival recession is also present [81].   In the current study, 66.7% of 
all patients were aged ≥60years and this predominance of older adults may explain why 
increased PPD was less apparent than increased CAL.  87.5% of non-deficient COPD patients 
were aged ≥60years compared to 39.7% of AATD which could also part explain why 
prevalence was higher in this group.  Additionally, even when periodontal disease is 
successfully treated, the recession can remain [217], thus it could be that some of the 
patients in this study, (in particular the older COPD group) have had previous disease which 
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has been subsequently treated but increased CAL is still noted.  Thus, it is important to be 
clear whether investigators are assessing active periodontitis or evidence of previous or 
cumulative disease.  The use of the presence of BoP may assist in this as when evident, BoP 
is suggestive of active inflammation and disease.  It may be practical to use a definition that 
utilises both PD and CAL such as the CDC-AAP criteria.  This would negate some of the 
problems of diversity of age and ensure patients with previous co-morbid disease but not 
active periodontitis are not misclassified as having a healthy periodontium. 
Both COPD and periodontitis share common risk factors including poor socio-economic 
status, smoking [143, 144] and age.  In addition to this, it is possible the link seen between 
the two conditions also reflects poor oral health in combination with poor nutrition, poor 
self-care behaviours and exposure to other environmental factors such as pollutants.  Many 
previous studies investigating relationships between COPD and periodontitis have failed to 
adjust for these common risk factors [83, 87, 143, 144].  The importance of this is recognised 
in a large meta-analysis which initially reported the odds ratio (OR) for having COPD in 
populations with periodontitis as 2.08, (95% confidence interval 1.48-2.91; p<0.001), yet 
after correction for known common risk factors the OR was reduced to 1.78 95% CI 1.23-
2.58 [143].   The numbers of participants in this current study prevented correction for all 
possible confounders but it was possible to correct for age and smoking pack year history 
using a binary regression method.  Before correction for age and smoking, most of the 
periodontal criteria indicated an increased prevalence of periodontitis in non-deficient COPD 
compared to AATD.  However, after correction, only average CAL ≥4mm still had a greater 
prevalence in the non-deficient COPD group, suggesting any uncorrected data should be 
interpreted with caution.  The adjusted  data concurs with the study of Hyman and 
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colleagues who only found an increased risk of COPD in patients with clinical attachment loss 
≥4mm [90].   
Non-deficient COPD patients were of a poorer socio-economic status, had lower income and 
were less well educated than AATD patients, a finding in keeping with previous studies 
comparing COPD and healthy controls [86, 91, 92, 94].  Regression analyses confirmed these 
variables did contribute to the association between periodontitis in non-deficient COPD 
compared to AATD.  The data from this study also shows non-deficient COPD patients had 
significantly reduced brush frequency; 46.7% brushing twice a day compared to 72.3% of 
AATD patients (p<0.001) which was also proven to be a significant confounder in the 
subsequent regression analysis.  In keeping with this, other studies have shown COPD 
patients have significantly reduced brush frequency [83, 85, 87] compared to the general 
population and thus is likely to be a crucial confounder when seeking associations and/ or a 
common pathophysiological process. 
Previous studies have reported associations with lung function and CAL in COPD [84, 87, 94].  
The data in this study also shows a significant negative correlation for FEV1: FVC ratio and 
average and maximum CAL in both respiratory cohorts.  This association is only seen for 
AATD when correlating with PPD.  There were no significant correlations for parameters of 
gas transfer and any periodontal measurement in the non-deficient groups, but some 
negative correlations did exist for the AATD group.  The reasons for this are not clear but 




Unfortunately, there are some limitations with this part of the study.  When taking 
periodontal measurements it is possible that placement of the tips of the measurement 
probes may not always be optimal leading to under and over-reporting of probing depth 
[79].  Insufficient patient numbers prevented inclusion of all potential confounders into 
single regression models, but attempts were made to account for these using separate 
regression models.  Ideally there would have been recruitment of  participants with no 
evidence of lung disease as a healthy control group, however as an alternative, the data was 
compared to the results from the Adult Dental Health Survey [101] as a surrogate control. 
 
4.2 Validation of commercially available ELISA kits for the 
measurement of salivary CRP and IL-8 
 
The use of saliva as a diagnostic fluid is gaining interest due to its relative abundance and 
non-invasive methods of collection [182, 219, 220].  Several studies have reported the 
potential use of salivary CRP as a clinical biomarker in thyroid disease [183] , metabolic 
syndrome [184], myocardial infarction[185, 186] and atherosclerosis [187], COPD [83, 188] 
and periodontitis [83, 189, 221].   
Most literature describing the results of biomarkers measured in saliva use commercially 
available ELISA kits for ease of implementation.   The kits provide some data in their product 
literature regarding validation for use, but it is our practice to conduct our own in-house 




It is generally accepted that a recovery between 80-120% is a reasonable indication that the 
assay is suitable for use with the type of sample being analysed [222].  However, the Abcam 
ELISA kit for CRP produced recovery of spiked samples 6-144%.  After contacting Abcam to 
discuss the results of our experiment they found that their product information leaflet was 
incorrect and the CRP ELISA kit had not been validated for use in saliva and consequently 
their product information leaflet was going to be amended. 
 
We were successfully able to confirm that the Salimetrics kit for salivary CRP was valid to be 
used as per the manufacturer’s protocol and at dilutions up to and including 1:10. Similarly, 
we were also able to validate the R&D kit for measurement of salivary IL-8, although the 
inter-assay variability was not as good for this kit as the Salimetrics kit, and thus data should 
be interpreted with that in mind. 
The link between local and systemic inflammation in the development and progression of 
inflammatory diseases is an area of great interest.  However, saliva varies between 
individuals both in terms of its composition and viscosity, both features which can interfere 
with assays and alter performance and results, otherwise known as matrix effects.  The 
dilution required is dependent on the content of proteins in the sample which is highly 
variable in saliva.  In addition, when manufacturers provide validation data they generally 
use healthy controls, yet patient samples are likely to be affected by the presence of 
inflammation and associated mediators which could further interfere with assay accuracy. 
Thus, to ensure an ELISA is suitable to analyse salivary samples, it is crucial that kits are 
appropriately validated to ensure results that are generated are both replicable and valid for 
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their experiment.  It appears that it is not sufficient to rely upon the validation data including 
in the product literature of all commercially available ELISAs for salivary CRP measurement 
and we would extrapolate this to other salivary measurement kits. 
 
4.3 Correlation of plasma with salivary CRP and IL-8  
 
Plasma hs-CRP was detectable in 100% of samples tested and was significantly higher in non-
deficient COPD patients than AATD patients.  This is in keeping with other studies showing 
increased plasma CRP in patients with COPD in comparison to healthy controls [28, 147, 162, 
163], although no studies compare it to AATD.  The reason for increased peripheral CRP is 
thought to be due to the sustained low grade systemic inflammation [23, 223, 224] 
commonly reported in COPD, but this has not been examined in AATD.   
Plasma IL-8 was detectable in 76.4% of samples tested, but more often detectable in COPD 
patients, than AATD; 93.6% versus 57.1%, p<0.001.  The mean IL-8 levels were similar in both 
groups but all values fell below the lower limit of quantification of the standard curve and as 
such further analysis was not possible.   This is in keeping with previous work which reports 
plasma IL-8 is not always detectable in the peripheral circulation [29, 38] and significant 
differences are not always apparent between disease and health [38, 201].  IL-8 is an 
inflammatory cytokine with a primary role in neutrophil chemotaxis at the site of insult or 
injury [199].  Therefore, it is not surprising that its levels are often undetectable in the 
peripheral circulation of healthy or otherwise stable patients.  
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Salivary CRP and IL-8 was detectable in 100% of samples tested. The mean values were 
greater in COPD patients for CRP, but no significant difference was seen for IL-8.  The results 
for salivary CRP replicate a previous study showing elevated levels in patients with COPD 
compared to health [188].  The lack of a difference in salivary IL-8 between health and 
disease has previously been reported [210].  However, the values in our patients were 
markedly raised in comparison to the mean values reported in other trials comparing 
salivary IL-8 in healthy patients to those with disease, and was comparative to the levels 
seen in patients with oral cancer [225, 226] which does support the hypothesis of increased 
local production of IL-8, a potent neutrophil chemoattractant and activator in these patients 
with predominantly neutrophilic mediated lung disease.  
A moderately significant positive relationship between plasma hs-CRP and salivary CRP was 
seen; which is in keeping with previous findings [192, 193] , but when the groups were 
analysed separately, the relationship persisted for AATD only.   The reasons for this are not 
clear but may reflect the greater difference in peripheral CRP between the two groups 
compared to the smaller although still significant difference in salivary CRP.  Additionally, it 
has previously been shown that correlations between peripheral and salivary CRP are 
weaker when the peripheral CRP is < 2.0mg/L compared to when levels are higher than this 
[193].  This may partly explain our findings as 47.7% of our patients had peripheral CRP 
<2.0mg/L.  A possible reason for this is that CRP is a large molecule and only transits into 
saliva from the peripheral circulation when it is in great abundance. Moderately positive 
correlations were seen in both groups for salivary CRP and salivary IL-8, suggesting that oral 
inflammation is characterized not only by locally produce inflammatory mediators, such as 
IL-8, but also by systemically produced inflammatory mediators which can travel to the site 
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of insult via the peripheral circulation and then enter the saliva by methods including cellular 
diffusion, ultra-filtration in salivary glands or through microvascular injury to the gingival 
epithelium [182, 227].   
 
4.4 Correlation of plasma and salivary CRP and IL-8 with 
demographic data, indices of lung function and disease 
severity 
 
No significant associations were seen for plasma hs-CRP, salivary CRP or salivary IL-8 and 
gender, age, smoking status or pack year history, co-morbid presence of diabetes mellitus, 
hypertension or vascular disease, age at leaving education, NS-SEC score or annual 
household income.   This is contradictory to previous work demonstrating peripheral [147, 
160] and salivary CRP to be higher in COPD than healthy non-smokers, although healthy 
smokers have a similarly raised salivary CRP to COPD patients [188].  Peripheral CRP has also 
been shown to be higher in patients with colonized airways [228].  As we did not measure 
this and therefore correct for it, it could be that the presence of microbial colonization in 
some patients reduced associations that would otherwise have been seen for peripheral CRP 
and our variables of interest.  Peripheral CRP is frequently raised in patients with ischaemic 
heart disease or atherosclerosis [153-156], but it is also raised in patients with subclinical 
disease [187].  The lack of relationships between measured CRP and presence of co-
morbidity may reflect several possibilities; the presence of sub-clinical or yet un-diagnosed 
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disease and the use of statin therapy in patients with confirmed disease.  Statins have been 
shown to reduce CRP [229], but this is not something we controlled for in this study. 
Plasma hs-CRP was significantly positively correlated with BMI and IMD quintile in AATD 
patients, but neither was associated with COPD patients.  Correlations with CRP and BMI 
have been seen previously [187] and are thought to occur due to the release of 
inflammatory cytokines from adipocytes and other inflammatory cells within adipose tissue.  
It is not clear why this observation was not seen in this study for non-deficient COPD 
patients, but the very varied levels of CRP may have masked this association. The correlation 
seen between increasing hs-CRP and IMD quintile suggests an increased inflammatory 
response in those patients living in more deprived areas as determined by their residential 
postcode.  This relationship was only seen for AATD patients but this could reflect the wider 
spread of this group across quintiles, whereas this was less so for the non-deficient COPD 
group.  This result suggests that poorer socio-economic status is associated with an 
enhanced inflammatory response, which is in keeping with previous observations showing 
patients with a lower SES are more likely to have chronic disease [230-232], although in this 
study the association was not seen for other measurements of socio-economic status.   
A weakly positive correlation was seen in the COPD group for salivary IL-8 and highest 
qualification gained. The reasons for this weak relationship are unclear and no logical 
explanation exists, thus the association is more likely to reflect a type one error occurring 
with a small sample size. 
No significant associations were seen for any inflammatory markers and GOLD stage of 
COPD severity, exacerbation frequency, presence of bronchitis, radiological evidence of 
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emphysema, use of inhaled therapies or any lung function parameter.  This could reflect a 
lack of sufficient participant numbers and a larger, appropriately powered study could 
explore this possibility further.  Previous work exploring associations of salivary CRP with 
lung function in COPD has also failed to find a correlation [188], although peripheral CRP is 
frequently reported to be inversely associated with exercise tolerance and lung function [28, 
147, 164, 165].  This association is felt most likely to be as a consequence of prolonged low 
grade systemic inflammation causing skeletal muscle dysfunction or muscle wasting [233].  
One possible theory therefore why we did not see this association in our patients could be 
that our patients do not have evidence of muscle dysfunction or wasting.  In future work this 
is something that could be addressed further by functional muscle assessment.  One possible 
reason for a lack of association with salivary inflammatory markers include the high 
percentage (85% and 53% of non-deficient COPD and AATD patients) using inhaled 
corticosteroids, which have been shown to reduce peripheral CRP levels [234] and thus 
potentially also in saliva. 
Salivary CRP was positively correlated with mMRC score for COPD patients and AATD 
patients, but no association was seen for plasma hs-CRP or salivary IL-8.  Finding an 
association between increased inflammation and worse mMRC score is not unexpected and 
has been reported previously for peripheral markers [161] and salivary markers, including 
CRP [188].  However, our data only finds an association for salivary CRP.  This may reflect 
that patients with worse mMRC scores tend to mouth breathe rather than inhale and exhale 
through the nasal passages.  This constant exposure of the oral mucosa to air pollutants 
could be the cause of the increased salivary but not peripheral CRP.  Further exploration of 
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4.5 Correlation of CRP and IL-8 with dental symptoms and 
indices of periodontitis 
 
No significant associations were seen for plasma hs-CRP, salivary CRP or salivary IL-8 and no. 
of teeth, frequency of tooth brushing, use of mouthwash or dental floss, last dental 
examination, previous dental disease, appearance of loss of bone, wider spaces between 
teeth, bleeding gums, loose teeth or previous dental extractions.  
Salivary IL-8 was significantly associated with patients reporting an appearance of longer 
teeth in the non-deficient COPD group and with painful teeth and gums in the AATD group, 
but did not correlate with any periodontal measurements or diagnoses of periodontitis.   
Plasma hs-CRP did not correlate with any of the periodontal measurements undertaken, 
although in the non-deficient COPD group, the plasma hs-CRP was significantly lower in 
patients with a diagnosis of periodontitis by maximum probing depth ≥4mm at any tooth 
and BPE score than those who were disease free.  This is the opposite of the findings of 
other work which has shown an increase in hs-CRP in patients with chronic periodontitis 
[171], and correlations with clinical measurements of periodontitis [171].  Salivary CRP was 
positively correlated with maximum probing depth (mm) and a diagnosis of periodontitis 
determined by PPD ≥4mm and BPE in AATD patients only. 
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The lack of association of salivary IL-8 and periodontal measurements may reflect the way IL-
8 was measured.  We used an ELISA kit which gave an assay value for the total amount of IL-
8 in the sample.  However, as previous work with GCF has demonstrated, there can be great 
variation in results depending if the total amount or the concentration of IL-8 is measured 
[203-205].  To calculate concentration rather than just total amount it would be necessary to 
measure salivary volume collected at the sampling time. 
 
4.6 Further Work 
 
In addition, other markers of systemic and local inflammation could be explored using a 
multiplex assay method which would generate richer data for analysis without needing 
additional volumes of biological fluids. 
Further analysis of inflammatory mediators in saliva should also include measurements of 
concentration rather than just total levels.  This is important as previous work has shown this 
can produce different results, certainly for IL-8, and this feasibly applies to other mediators 
too.  Additionally, the measurement of markers in GCF could also be advantageous rather 
than analysing mediators in saliva which is more easily contaminated and of which 
composition can change.  Previous work has also confirmed GCF levels of inflammatory 
markers correlate well with peripheral levels of the same markers [171]. 
 
Exploring the enhanced neutrophilic inflammatory hypothesis relating chronic lung disease 
and periodontitis could be achieved by isolating neutrophils from patients with and without 
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COPD and within these groups further sub group analysis of those patients with periodontitis 
and those with a heathy periodontium.  Neutrophil function could then be assessed by 
measuring chemotaxis and phagocytosis ability and determining if the neutrophils from 
patients with COPD behaved in a similar manner to those with periodontitis and if these 
neutrophils had impaired function in comparison to age matched controls without COPD or 
periodontitis.  A further interesting angle would be to explore the microbiome present on 
dental plaque and compare it to the microbiome from respiratory samples such as sputum 
or bronchoalveolar fluid.  This would help determine if there is an association between the 
two compartments as at least some of the same microbiome would be expected to be 
present in both lung and oral cavity if there was a genuine association relating to overspill 
theory from oral cavity to the respiratory system or from haematogenous dissemination of 
microorganisms. 
We compared non-deficient COPD with AATD but if further work was to be undertaken it 
would be useful to have a healthy, age-matched cohort to be used as a control group.  This 
would be helpful in particular if looking at the hypothesis of enhanced neutrophilic 
inflammation as this would not be seen in the healthy control group and as such if this was 
the mechanism of action, clear differences should be apparent.   
Some of our results may be affected by relatively small sample sizes.  If this work was to be 
replicated in the future, it would be beneficial to have a larger cohort recruited to minimise 
type 1 errors and allow for larger regression models to be used to account for the large 
number of confounding variables.  Statistical power calculations would be useful to 
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determine the numbers of patients that would need to be recruited to each group to 






In summary, the criterion used to diagnose periodontitis in epidemiological studies has a 
significant impact on the prevalence and associations with other chronic diseases. Using 
strict criteria this data indicates an increased prevalence in non-deficient COPD compared to 
AATD but an association with the severity of physiological impairment is stronger in AATD 
suggesting the deficiency may enhance not only lung destruction but also periodontal 
damage irrespective of other demographic confounders. 
It is important to recognise the burden of periodontal disease as co-morbidity in other 
chronic diseases so at risk individuals can be managed appropriately at an early stage.  
Ascertaining accurate prevalence data provides information on the social and economic 
effects of the disease and its’ implication/s in developing community health education 
programmes.  Further accurate data will assist with research into other areas of chronic 
comorbidity associated with oral disease and potentially the development of beneficial 
treatments and interventions. 
The available evidence from this study still provides support for the hypothesis that COPD 
and periodontitis could be causally linked; raising the possibility that treatment of one could 
influence the severity and progression of the other. There are similarities in disease 
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mechanisms (that of neutrophilic inflammation and connective tissue loss) that suggest a 
shared pathophysiology and support epidemiological evidence of association.  However, the 
presence and severity of periodontitis must be defined using robust criteria and second, the 
diagnosis of COPD must be confirmed according to international standards; this will require 
close collaboration between dentists and physicians.  Third, known relevant confounding 
factors must be recorded and considered, and this will require a significant sample size to 
allow appropriate statistical modelling.   Finally, the inflammatory profiles (systemically or 
locally) in groups of patients with COPD and periodontitis need to be compared with that of 
matched patients with COPD and no periodontitis.   Such studies could then be used to 
design appropriately powered interventional trials to determine whether treating 
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This questionnaire is voluntary. All answers are kept anonymously, but you 
are under no obligation to disclose information you would rather withhold. 
1. Current Postcode 
………………………………………………………………………………………………………………………………….. 
2. At what age did you finish your continuous full-time education at school, college or 
university?............. 
3. Highest academic qualification held: GCSE/O-Level    A-level   
  
Degree     Post-graduate  
4. Any vocational qualification?   Yes             No Details 
……………………………………………… 
5. Are you currently in a paid job?     Yes             No 
6. If no, have you ever had a paid job?  Yes             No       Year left last paid 
job……………………  
7. What is the title of your 
job?....................................................................................................................... 
8. Are you:  Full Time   Part Time  




10. What is the house-hold annual taxable income (excluding benefits) before tax? 
£0-£10k  >£10k - £20k  >£20k - £40k   >£40k - £80k 











Dental Health Questions: 
1. How often do you brush your teeth?   Not every day            Once a day    >2 times 
a day 
2.  Do you regularly floss your teeth?          Yes             No 
3.  Do you regularly use mouthwash?         Yes             No 
4. How long has it been since you last had a dental examination? 
 Within 6/12         Within year         Within 2 years         Greater than 2 years        
 Never 
 
5. Have you ever been told that you have periodontal disease or gum disease?  Yes            
 No 
6. Has a dentist ever told you that you had lost bone around your teeth?   Yes            
 No 
7. Have you noticed in recent years that the space between your teeth gets wider, or that 
‘black triangles’ have developed between your teeth?       
Yes             No 
8. Have you noticed a recession of your gums, so that teeth appear longer?  Yes            
 No 
9. Have you had painful gums?   Yes             No 
10.  Do your gums ever bleed?   Yes             No 
11. Are your teeth loose?    Yes             No 
12. Have you had any adult teeth extracted due to gum disease?   Yes             No 
13. If so, how many?    1   1-5   6-31  
All 
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